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Abbreviations 
 
ABC ATP binding casette 
ACP ABC transporter ATPase encoded by CpB0255 gene of Chlamydophila pneumoniae 
AG arabinogalactan 
Alum Aluminum hydroxide gel 
ATB ABC transporter ATPase encoded by Rv0986 gene of M. tuberculosis  
ATPase adenosine triphosphatase 
BCG bacillus Calmette-Guérin 
bp base pair 
C. pneumoniae Chlamydophila pneumoniae 
CAD coronary artery disease  
CFU colony-forming units  
DAB diaminobenzidine tetrahydrochloride  
DC dendritic cell  
DNA deoxyribonucleic acid 
E. coli Escherichia coli 
EB elementary body 
ELISA enzyme-linked immunosorbent assay 
Fig. Figure 
HIV human immunodeficiency virus 
HRP horseradish-peroxidase  
hVps human vacuolar protein sorting 
Icl isocitrate lyase  
IFN interferon  
IFU inclusion forming unit 
Ig immunoglobulin 
IL interleukin 
Inc inclusion membrane protein 
kDa kilodalton 
LAM lipoarabinomannan  
LB Luria-Bertani 
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LcrE low-calcium response E protein 
LcrH low-calcium response H protein 
LDL low density lipoprotein 
LM lipomannan  
M. bovis Mycobacterium bovis  
M. smegmatis Mycobacterium smegmatis 
M. tuberculosis Mycobacterium tuberculosis 
MDR Multidrug-resistant 
MW molecular weight 
NK cells natural killer cells 
OD optical density 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PIMs phosphatidylinositol mannosides 
pΔRC eukaryotic expression vector 
RB reticulate body 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
TB tuberculosis 
TDM trehalose dimycolate 
Th T helper 
TTSS type III secretion system 
WHO World Health Organization 
XDR Extensively drug-resistant  
Yop Yersinia outer-membrane protein  
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1. Introduction  
 Metabolism and pathogenicity of intracellular bacteria (mycobacteria, Chlamydophila 
pneumoniae were studied in the laboratory when I started my Ph.D. studentship. Possible 
vaccine targets were identified, RNA metabolism, glyoxylate cycle, regulatory proteins were 
investigated. My work focuses on recombinant BCG as an improved vaccine candidate, 
ABC transporter ATPase of C. pneumoniae and Mycobacterium tuberculosis, and low 
calcium response protein E as possible components of vaccines. There is a big competition 
in finding new drugs and vaccines among biotechnology and pharmaceutical companies and 
there is a vast difference between our budget and theirs. The investigation of intracellular 
bacteria is a very important research area. The survival and spread of these bacteria depend on 
their ability to replicate inside the eukaryotic cell. The similar life habit might be realized 
through the homologous proteins. 
More efficient vaccination against C. pneumoniae and M. tuberculosis would be a 
great step in the prevention and treatment of these infections. For possible vaccine candidates 
we cloned LcrE protein encoded by lcrE of type III secretion system from C. pneumoniae, as 
well as chlamydial ABC transporter ATPase protein. The genes for these vaccine candidate 
proteins were cloned into Escherichia coli expression vector and E. coli was transformed with 
them. 
The survival of M. tuberculosis in infected macrophages requires the activity of 
isocitrate lyase (Icl), a key enzyme in the glyoxylate cycle. icl gene was cloned into E. coli 
and E. coli-mycobacterium shuttle plasmids and E. coli and Mycobacterium bovis BCG were 
transformed with them.  
 BALB/c and ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J) mice 
were immunized either with the purified proteins or with recombinant M. bovis BCG 
bacterium and a eukaryotic expression vector. 
 
1.1  The pathogens and the diseases 
 Tuberculosis (TB) has troubled humankind throughout history. It has been a leading 
cause of death, and still is in low-and middle-income countries. TB is a classic example of 
airborne infection. The causative agent, M. tuberculosis, is a very successful pathogen. One 
third of the human population is infected with this bacterium. WHO declared TB a public 
health emergency in 1993. The annual World TB Day on 24 March marks the day in 1882 
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when Robert Koch detected the TB bacillus [1]. TB, also known as “morbus hungaricus” in 
Hungary, was found in the spines and skulls of the over 4000-year-old Egyptian mummies 
[2].  Despite the earlier forecast, TB is still here and the aim of the StopTB Strategy is to 
radically reduce the global burden of TB by 2015, unfortunately, this expectation seems 
overly optimistic [3]. The genus Mycobacterium comprises more than 140 well-characterized 
species [4], most of them are non-pathogenic to human being.  Several species are, however, 
associated with human disease such as tuberculosis or leprosy. The causative agent of TB is a 
fairly large, non-motile, rod-shaped bacterium, belongs to the obligate aerobe group and it is 
found mainly in the well-aerated upper lobes of the lungs. The rods are 2-4 microns in length 
and 0.2-0.5 microns in width. It can not be classified by Gram's staining method due to its 
resistance to acid-alcohol following coloration with phenicated fuchsin (Ziehl-Neelsen stain). 
The mycobacterial cell wall complex contains peptidoglycan and high concentration of lipid 
which assist to survive inside the macrophages, and cause resistance to many antibiotics, 
impermeability to stains and resistance to osmotic lysis [5]. The lipid complex which makes 
up over 60% of the cell wall, consists of three major components: mycolic acids, cord factor 
(trehalose dimycolate, TDM) and wax-D. This unique cell wall structure and its 
characteristics play an imperative role in the pathogenicity of mycobacteria and is one of the 
main reasons of the resistance to most antibiotics [6, 7]. The cell wall consists of two parts: an 
outer part and the core of the cell wall. The cell wall core is made up of peptidoglycan 
covalently linked to arabinogalactan (AG) and mycolic acids subsequently. The outer layer 
consists of free lipids, linked with fatty acids. Different cell wall components such as 
phosphatidylinositol mannosides (PIMs), lipomannan (LM), and lipoarabinomannan (LAM) 
are also found in it. TDM inhibits the phagosome-lysosome fusion and plays a part in the 
maintenance of granulomatous response. LAM inhibits the phagosome maturation by 
inhibiting the Ca2+/calmodulin phosphatidyl inositol-3-kinase hVps34 pathways [8]. Infection 
with M. tuberculosis in healthy people is generally asymptomatic, because of the “wall off” 
by the immune system. TB usually attacks the lungs but can also cause extrapulmonary 
symptoms.  It is transmitted interpersonally via droplets from the throat and lungs of infected 
people. The symptoms of active TB are coughing, chest pain, weight loss, and fever. TB is 
either latent or active. While active TB causes symptoms, latent TB does not, nor can it 
spread. Development of active TB is only 5% to 10% of all infections.  
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Fig. 1 The intracellular lifestyle of M. tuberculosis [9] 
 
Figure 1 shows how bacteria, after inhalation, are phagocytosed by the alveolar macrophages. 
This eventuate leads to a pro-inflammatory response and the cells of the innate and adaptive 
immune systems will be recruited. The result is the formation of a granuloma, in which the 
bacteria are capable of living for an extended time. Deadening of the immune system assists 
the granuloma development and the reactivation of the bacteria.  
 According to the phylogenetic analysis of 16S and 23S DNA sequences, the family of 
Chlamydiaceae is divided into two genera, Chlamydia and Chlamydophila. The genus 
Chlamydia consists of 3 species, Chlamydia trachomatis, C. muridarum and C. suis.  In the 
genus Chlamydophila there are 6 species, Chlamydophila pneumoniae, C. psittaci, C. 
pecorum, C. abortus, C. caviae and C. felis [10]. Chlamydiaceae were first identified as a 
virus. The best known members of Chlamydiaceae, are the human genital and ocular 
pathogen C. trachomatis and the respiratory pathogen C. pneumoniae. According to the 
seroepidemiological studies, 50–70% of the adult population worldwide is seropositive to C. 
pneumoniae [11]. Respiratory infections caused by C. pneumoniae are often mild with no 
symptoms, or the only symptom of being persistent cough [12], and in most cases they 
probably remain undiagnosed. An asymptomatic and thereby untreated chlamydial infection 
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may become persistent and lead to chronic conditions. Also, incomplete immunity after 
natural infection facilitates repeated infections that may exacerbate pathology and chronic 
diseases. The association of C. pneumoniae with chronic human diseases was first shown in 
seroepidemiological studies, which demonstrated the association of antibodies to C. 
pneumoniae with acute myocardial infarction [13]. Later, the association of the infection with 
other chronic diseases, such as asthma and chronic bronchitis, has been suggested [14]. The 
seroepidemiological data linking C. pneumoniae infection to coronary artery disease (CAD) 
have also been supported by detection of antigens by immunocytochemistry or nucleic acids 
of the organism by PCR in the affected tissues [15, 16, 17]. Yet, the timing of C. pneumoniae 
infection and development of arteriosclerosis is poorly understood [18, 19, 20, 21, 22]. 
Although acute chlamydial infections are curable with antibiotics, the antimicrobial therapy, 
used in treatment of acute infections, may not be effective in resolving the infection in the 
associated chronic conditions [23, 24]. Therefore, vaccination has been suggested to be an 
effective strategy for prevention and also controlling the chronic chlamydial infection. 
 
1. 2 Sheltered life 
 A large number of bacteria are able to live and survive in the eukaryotic cells. In order 
to adapt to this special lifestyle, they need to create a unique niche and try to avoid the attack 
of the humoral immune system [25]. In the usual scenario, after the invasion, macrophages 
ingest the bacteria and they are trapped by the phagosomes. After phagocytosis they are 
located in the membrane-bound vacuole (phagosome). In the absence of intracellular survival 
mechanisms, phagosomes-containing the bacteria-fuse with the lysosomal compartment thus 
creating the phagolysosome. This environment in the macrophages can be fatal for the 
bacteria. Intracellular bacteria are able to block this step and survive in the hostile 
environment. Some facultative and obligate intracellular bacteria possess special strategies to 
survive or avoid the hostile environment. 
 Yersinia species can prevent phagocytosis, Salmonella species are able to modify the 
phagocytosis. Listeria and Shigella can lyse the vacuolar membrane to escape into the 
cytosol, Legionella species block the phagolysosome fusion, M. tuberculosis blocks or 
attenuates phagolysosomes [26]. 
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1.2.1 Survival strategy of M. tuberculosis 
 A survival of M. tuberculosis in infected macrophages requires the activity of 
isocitrate lyase (Icl), a key enzyme in the glyoxylate cycle. The glyoxylate shunt permits the 
effective utilization of two-carbon compounds, such as acetate (from the β-oxidation of fatty 
acids), to satisfy carbon requirements [27]. The glyoxylate cycle is required for the virulence 
of other bacteria and fungi [28, 29]. In mycobacteria, Icl has a dual role in the metabolism of 
fatty acids. It participates in the methylcitrate cycle too [30]. β-oxidation of odd-chain or 
branched-chain fatty acids results in the production of propionyl-CoA which is toxic for 
bacteria and fungi [31, 32]. Propionyl-CoA is metabolized in the methylcitrate cycle. The 
other way to use up proponyl-CoA is the methylmalonyl pathway. It requires a vitamin-B12-
derived cofactor [33]. 
 A key to the intracellular survival of M. tuberculosis is its ability to prevent the fusion 
of phagosomes containing the internalized bacterium with the lysosomal system of the host 
cell. The addition of certain exogenous fatty acids modulates phagosome maturation, resulting 
in the killing of pathogenic bacteria, whereas other fatty acids stimulate pathogen growth [34]. 
Thus the role of lipids is multifaceted. 
 
1.2.2 Survival strategy of C. pneumoniae – the Chlamydia inclusion 
 The members of the family Chlamydiaceae have a unique two-phased developmental 
cycle. It is initiated by endocytosis of an EB, the infectious but metabolically inactive form of 
chlamydia by a eukaryotic host cell. Inside the vesicle, the bacterium is able to inhibit the 
phagolysosomal fusion. At about 8 h after infection, EB begins to changes in its morphology 
and differentiate into RB, the metabolically active form of chlamydia and start to multiply by 
binary fission. 36 h after infection, RB reorganize into EB, which are able to lysis of the host 
cell (Fig. 2) 
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Fig. 2 The developmental cycle of C. pneumoniae [35] 
 
  Like many other human pathogens such as Yersinia, Salmonella, Shigella, 
Pseudomonas aeruginosa and pathogenic E. coli, C. pneumoniae also posseses a TTSS, 
enabling the bacteria to secrete effector proteins into the cytosol of the infected cell [36, 37]. 
This system is activated during the intracellular phase of the chlamydial replicative cycle and 
is responsible for both the insertion of chlamydial proteins into the inclusion membrane that 
separates the growing chlamydial microcolony from the host cell cytoplasm, and also for 
secretion of proteins into the host cell cytoplasm which modulates the cell response to 
ongoing chlamydial replication. The virulent elementary body is protected against the 
environmental effects [38]. There is a persistent phase where chlamydiae are able to remain 
alive for a long time. Supposedly, the persistent phase may have an important role in chronic 
infection [39]. 
  In the case of the pathogenic vacuole, Rab GTPases (Rab4, 11, 1, 6 and 10) are able to 
associate with the inclusion membrane which permit interaction with the ER and Golgi-
derived vesicles. Lipid droplets and neutral lipid storage organelles are issued from the host 
cytoplasm by translocation across the inclusion membrane. The modification of the inclusion 
membrane is ensured by the integral membrane proteins. Incs interact with the Rab GTPases 
and participate in the recruitment of Rab GTPases to the inclusion membrane, which play a 
key role in the inclusion biogenesis [40]. 
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1.3 Vaccination against intracellular bacteria 
 Vaccination against human pathogens is one of the best ways to put an end to the 
serious effects of certain diseases. In clinical use, vaccines consist of either killed or 
attenuated microbes such as influenza, polio, measles, tuberculosis or subunits of the 
organisms (Haemophilus influenzae type B, Meningococcus A and C, Hepatitis B) [41]. 
Long-lived immune responses (cell-mediated response and production of protective 
antibodies) are induced by this type of vaccines. Most current vaccines are able to induce the 
immune response and effective for diseases mentioned above. In addition, cell-mediated 
immunity (mediated by T lymphocytes) is crucial in the immune protection of intracellular 
microbes.  Antigen-presenting cells (macrophages or dentritic cells) produce IL-12, which is 
the inducer of the functional Th1 response and the protection mediator is the effector 
cytokine, IFN-γ. At the same time, for diseases such as AIDS, malaria and other infections 
caused by intracellular pathogens, effective vaccines are not available [42]. 
 
1.3.1 BCG vaccine versus new vaccines for tuberculosis 
 Although M. bovis BCG (Bacille Calmette-Guérin) is the only approved vaccine used 
for the prevention of TB in humans, the protective efficacy of the BCG vaccine varies widely 
in different parts of the world, reaching a maximum of 78 % [43]. The vaccine contains live 
attenuated strain of M. bovis which was attenuated between 1908 and 1920 by 231 serial 
passages. During 13 years in vitro passage, the virulent strain was seen to be less virulent for 
animals. BCG vaccine was first used in humans against tuberculosis in 1921. Since that time, 
BCG is the most widely used vaccine all over the world, but its protective value as anti-TB 
vaccine is questionable. BCG can protect children against severe forms of the disease, 
particularly meningitis, but it seems to be much less effective, or even ineffective against the 
most prevalent form, pulmonary tuberculosis in adults. To reduce the global burden of TB, 
new vaccination strategies are needed, not only in newborns, but also in adolescents and 
adults.  
 Most current efforts to improve the level of protective immunity provided by BCG 
include the development of recombinant BCG vaccines expressing different antigens [44]. A 
number of vaccines, diagnostic technologies, and drugs are in clinical development. 
Mycobacterium smegmatis, first identified in 1884, is a rapidly growing saprophyte, it can 
propagate one generation every 1-3 h. It is non-pathogenic and commensal in humans [45, 
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46], and it acts as a powerful cell immunity adjuvant. Unlike other mycobacterial species, 
such as M. tuberculosis, that survive in host cells by inhibiting phagosome maturation, M. 
smegmatis is rapidly destroyed by phagolysosomal proteases in the phagosomes of infected 
cells [47, 48]. M. smegmatis has a number of properties that can make it an effective vaccine 
vector. This fast-growing mycobacterium is unable to arrest phagolysosome maturation and 
cannot evade intracellular killing [49, 50, 51, 52]. Moreover, its rapid clearance by the host 
differs from that of the M. tuberculosis or even the vaccine strain M. bovis bacillus Calmette-
Guérin [48]. Furthermore, M. smegmatis has been used as a vaccine vector because it 
activates dendritic cells and induces CD8-mediated immune responses [53, 54, 55, 56]. 
Finally, killed M. smegmatis has been shown to provide the same adjuvant activity as M. 
tuberculosis during the induction of experimental autoimmune encephalomyelitis [57]. 
 
1.4 Possible vaccine candidates  
 
1.4.1 ABC transporter ATPase 
 ABC transporter ATPase encoded by Rv0986 gene of M. tuberculosis H37Rv strain, is 
involved in cell adhesion and entry [58], and plays a part in the inhibition of phagosome-
lysosome fusion [59]. The expression of ATPase protein gene is up-regulated by at least 20-
fold in mycobacterium during infection [60]. These are the reasons why it can be a suitable 
vaccine candidate. The proteins which are involved in bacterial cell invasion might be similar 
in different intracellular bacteria. C. pneumoniae has a homologous ATPase protein, encoded 
by CpB0255 gene. The purpose of this study was the cloning, over-expression and 
purification of chlamydial ABC transporter ATPase protein; examination of the 
immunogenicity and the protective ability of subcutaneous recombinant protein vaccination 
with chlamydial ABC transporter ATPase against C. pneumoniae infection in mice. 
 
1.4.2 LcrE protein  
 The protein encoded by lcrE is homologous to Yersinia YopN, a surface protein [61] 
thought to be a TTSS response regulator, which senses either a host cell contact in vivo or 
Ca2+ concentration in vitro. It is located at the outermost position in the TTSS structure [62]. 
The fact that LcrE protein is exposed in the EB suggests that the TTSS apparatus may also be 
fully assembled in extracellular chlamydiae, possibly to be used in early events of cell 
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infection, e.g. in order to assist the entry of chlamydiae into the host cell and the successful 
establishment of early chlamydial inclusion vacuole. [63]. Herrmann et al. [64] detected 
increasing expression of LcrE towards the end of the C. pneumoniae infection cycle. The fact 
that LcrE appears to be presented to antibodies on the surface of EB makes this protein a 
possible vaccine candidate. Sambri et al. [65] described a protective effect of recombinant 
LcrE protein mixed with Freund’s adjuvant given subcutaneously against C. pneumoniae 
challenge in a hamster model. The protective effect of immunization with LcrE protein mixed 
with Freund’s or Alum adjuvant against experimental C. pneumoniae infection in mice was 
earlier described by our group [66]. Studies have shown that cell-mediated immunity is 
necessary for protection against C. pneumoniae in mice. In immunization models DNA has 
been used to induce Th1 type immunity against C. pneumoniae. In several studies, a partial 
protection against the infection has been observed in mice vaccinated with naked DNA 
carrying genes for major outer membrane protein, 60 kDa heat shock protein or ADP/ATP 
translocase [67, 68, 69].  
The purpose of our study was to test the immunogenicity and the protective ability of 
intramuscular lcrE-DNA immunization and lcrE-DNA priming/recombinant LcrE protein 
booster immunization regime against C. pneumoniae infection in mice.  
 
1.5 Aims 
The purpose of this study was:  
• The over-expression and purification of chlamydial LcrE and ABC transporter 
ATPase proteins in large quantities  
• To clone the genes for these vaccine candidate proteins into Escherichia coli 
expression vector and to transform E. coli with them 
• The effect of Icl: 
o icl gene was cloned into E. coli and E. coli-mycobacterium shuttle plasmids 
and E. coli and Mycobacterium bovis BCG were transformed with them. 
• Comparison the immunogenicity and the ability of protein vaccination, BALB/c and 
ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J) mice were immunized 
either with the purified proteins or with recombinant M. bovis BCG bacterium and a 
eukaryotic expression vector. 
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2. Materials and methods 
 
2.1 Bacterial strains and growth conditions 
M. bovis BCG, E. coli DH5α, E. coli HB101 and C. pneumoniae CWL029 (ATCC) 
strains were used. E. coli strains were routinely grown in LB (Luria-Bertani) medium 
supplemented with the appropriate antibiotic(s). M. bovis BCG was grown in Middlebrook 
7H9 broth or 7H10 agar (Difco Laboratories, Detroit, MI, USA) enriched with 10% 
Middlebrook OADC (oleic acid/albumin/dextrose/catalase) (Difco) and 0.05% Tween 80 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) with the appropriate antibiotic. C. 
pneumoniae was propagated in HEp-2 cells. 
 
2. 2 Plasmid constructions 
 
2.2.1 LcrE plasmids 
 A 1200 bp fragment containing the lcrE (GeneID: 895078; Locus tag: CPn0324) gene 
was amplified by PCR, using the following primers: E1 5’-GGA GGC ATA TGG CAG CAT 
CA-3’ and E2 5’-CAC AGG ATC CGT ATT GGT TTT GCA TGG C-3’ for ligation to 
prokaryotic expression vector (p6HisF-11d), the resulting plasmid was pLCRE. E3 5’-GCT 
AAG CTT ATG GCA GCA TCA GGA-3’ and E4 5’-TTA GGG CCC GTA TTG GTT TTG 
CAT GGC-3’ for ligation to eukaryotic expression vector (pΔRC) [70]. C. pneumoniae 
CWL029 DNA was used as template. Primers were planned by using the sequence of 
CWL029 [71]. 
 PCR was performed in a GeneAmp II thermocycler (Applied Biosystems, 
Foster City, CA, USA) with Advantage GC cDNA polymerase (Clontech, Mountain 
View, CA, USA) and the amplification conditions were set as recommended 
by the manufacturer. The amplified DNA for eukaryotic expression vector 
(pΔRC) was digested with HindIII and ApaI and inserted into the pΔRC by 
digesting it with the same enzymes. The resulting plasmid was pΔRCLcrE. For 
DNA immunization we purified recombinant pΔRCLcrE and pΔRC plasmids in large scale by 
GenElute™ HP Endotoxin-Free Plasmid Megaprep Kit from 
Sigma. 
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2.2.2 ABC transporter ATPase plasmid 
 A 681 bp fragment containing the gene of ABC (ACP) (GeneID:33241335; Locus 
tag:CpB0255) gene from C. pneumoniae was amplified by PCR, using the following primers: 
AB3 5’-GGG CAT ATG TCC TTA CTT ATA GAA-3’ and AB4 5’-AAC GGA TCC AGA 
GGG AGT GTT TTC-3’ and C. pneumoniae CWL029 DNA as template. Primers were 
planned by using the sequence of CWL029 [71].  This fragment was digested with NdeI and 
BamHI and inserted into p6HisF-11d(icl) by digesting with the same enzymes and replacing 
the icl gene. The resulted plasmid was pACP. 
PCR was performed in a GeneAmp II (AppliedBiosystems, Foster City, CA, USA) 
thermocycler with Advantage GC cDNA polymerase (Clontech, Mountain View, CA, USA) 
and the amplification conditions were set as recommended by the manufacturer.  
 
2.2.3 pMV262(icl) plasmid 
 We constructed pMV262(icl), which carries icl after the mycobacterial icl promoter 
(GenBank accession no. CAE55284.1) in pMV262 [72]. I1 5’-ACT ATC TAG ATC CGC 
AGG ACG TCG A-3’ and I2 5’-GTA AGC TTC AGA CTA GTG GAA CTG G-3’ primers 
were used to synthetize icl with M. tuberculosis H37Rv chromosomal DNA as template. 
Primers were planned by using the sequence of H37Rv [73]. The amplified DNA was cut with 
XbaI and HindIII and inserted into pMV262 opened with the same enzymes. 
 PCR was performed in a GeneAmp II thermocycler (Applied Biosystem, Foster City, 
CA, USA) with Advantage GC cDNA polymerase (Clontech, Mountain View, CA, USA) and 
the amplification conditions were set as recommended by the manufacturer.  
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Table 1.  Summary of genes, primers and PCR reaction conditions 
Genes Primers PCR reaction conditions 
 
lcrE 
E1 5’-GGA GGC ATA TGG CAG CAT CA-3’ 
E2 5’-CAC AGG ATC CGT ATT GGT TTT 
GCA TGG C-3’ 
 
ABC 
transporter 
ATPase 
AB3 5’-GGG CAT ATG TCC TTA CTT ATA 
GAA-3’ 
AB4 5’-AAC GGA TCC AGA GGG AGT 
GTT TTC-3’ 
 
 
icl 
I1 5’-ACT ATC TAG ATC CGC AGG ACG 
TCG A-3’ 
I2 5’-GTA AGC TTC AGA CTA GTG GAA 
CTG G-3’ 
 
 
 
94 º C  1 
   94 º C  20”     
   55 º C  20”  30x
68 º C  2’ 
68 º C  3’ 
    4 º C     ∞ 
 
 
2.3 Gene copy number determination  
The High Pure PCR Template Preparation Kit (Roche Diagnostic GmbH, Mannheim, 
Germany; Cat. No.: 1796828) was used for DNA Extraction. Each DNA sample was analysed 
in triplicate. The reaction volume was 15 µl, containing 3 µl of DNA, 1 µmol/l of each of the 
primers (2µl), 7.5 µl of reaction buffer (IQTM 2X Supermix, Bio-Rad Laboratories, Hercules, 
CA, USA) 0.6 µl of EVAGreen (20x EVAGreenTM Biotium Inc., Hayward, CA, USA) and 1.9 
µl of distilled water.   We used the forward primer 5’-AGC GCA TAT GTC TGT CGT CGG-
3’ and reverse primer 5’-GTA AGC TTC AGA CTA GTG GAA CTG G-3’ for icl. The 
reference gene (GeneBank accession no. O53899) primer set was 5’-TGG CAT ATG AAC 
CGG CAA CCT ATC-3’ and 5’-GAG GAT CCT CAT TCA TAG GAC GTG-3’. The primer 
sets have very similar efficiencies. A BIO-RAD CFX 96 instrument (Bio-Rad, Hercules, CA, 
USA) was used for quantitation. The PCR conditions were initial denaturation at 95 °C for 10 
min, followed by 35 cycles of denaturation (94 °C for 20 s), annealing (55 °C for 30s) and 
extension (68 °C for 45s). The emitted fluorescence was measured after the extension step. 
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 Quantitation was performed by online monitoring for identification of the exact time 
point at which the logarithmic linear phase could be distinguished from the background 
(crossing point). The gene copy number was calculated by the ΔCt method with Bio-Rad CFX 
Manager 1.1 Gene Expression software. 
 
Table 2. Summary of primers and conditions of RT-PCR 
Genes Primers Conditions 
 
 
icl 
5’-AGC GCA TAT GTC TGT CGT 
CGG-3’  
5’-GTA AGC TTC AGA CTA GTG 
GAA CTG G-3’ 
 
Reference gene 
(GeneBank accession 
no. O53899) 
5’-TGG CAT ATG AAC CGG CAA 
CCT ATC-3’  
5’-GAG GAT CCT CAT TCA TAG 
GAC GTG-3’ 
 
     95 °C  10 min 
94 °C  20 s   
          55 °C  30 s        35x   
             68 °C 45 s                
              4 ºC     ∞ 
 
 
2.4 Protein analysis techniques 
 
2.4.1 Expression of LcrE and ACP      
For over-expression, E. coli HB101(pGP1-4) cells carrying either pLCRE or pACP  
plasmids were grown and treated according to the method of Tabor and Richardson [74]. 
Briefly, cells containing the plasmids were grown at 32 °C in LB medium in the presence of 
the required antibiotics (ampicillin, kanamycin). Over-expression of proteins was induced by 
shifting the temperature to 42 °C for 20 min. After induction, the temperature was shifted 
down to 37 °C for an additional 30 min or longer, cells were harvested by centrifugation and 
cell pellets were frozen. 
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2.4.2 Purification of LcrE and ACP 
Cell lysates were prepared by resuspending the frozen cell pellets in lysis buffer (50 
mM sodium phosphate, 300 mM sodium chloride, pH 7,0) containing protease inhibitor 
cocktail (Sigma) and lysozime (Sigma) (0,75 mg/ml). Bacteria were opened by sonication. 
After centrifugation, either LcrE or ACP proteins were purified from the supernatant using 
TALON CellThru Resin (Clonetech), following the vendor’s instructions. 
 
2.4.3 Protein detection 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to Laemmli [75]. Gels were stained with Coomassie brillant blue [76]. 
 
2.4.4 Electroporation of M. bovis BCG 
Competent M. bovis BCG prepared in 10% glycerol was transformed with pMV262 or 
pMV262(icl) by electroporation with a Gene Pulser (Bio-Rad, München, Germany) set at 2.5 
kV and 25 µF, and with the pulse controller resistance set at 1,000 Ω. Transformed BCG was 
selected on Middlebrook 7H10 agar plates supplemented with 30 µg/ml kanamycin.  
 
2.5 Immunological methods and toxicity testing 
 
2.5.1 Immunization method of LcrE 
Specific-pathogen-free 13-week-old, female BALB/c mice were obtained from 
Charles River Laboratories UK (Kent, England). Mice were maintained under standard 
husbandry conditions at the animal facility of the Department of Medical Microbiology and 
Immunobiology, University of Szeged and were given food and water ad libitum. The mice in 
groups of 10 were immunized: (Group 1) with 50 µg pΔRC plasmid intramuscularly once and 
4 weeks later with the purified LcrE protein diluted in PBS at a dose of 20 µg mixed with 25 
µl Alum (Aluminium hydroxide Gel, Sigma) in 150 µl subcutaneously into the tail base; or 
(Group 2) with 50 µg pΔRCLcrE plasmid intramuscularly two times with 4-week interval, or 
(Group 3) with 50 µg pΔRCLcrE plasmid intramuscularly once and 4 weeks later with 20 µg 
LcrE  protein combined with Alum adjuvant. As control we used Group 4; mice were 
immunized with 50 µg pΔRC plasmid intramuscularly two times with 4-week interval. Two 
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weeks after the last immunization blood was collected in heparinized capillaries from the 
retro-orbital plexus. All experiments complied with the University of Szeged guidelines for 
the use of laboratory animals. 
 
2.5.2 Mouse experiments to study the survival of the recombinant BCG 
We used ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J) mice,16 
females  per group and their weight ranged from 25-30 g with the genetic background of a 
mixture of C57BL/6 and a particular 129 strain from Jackson Laboratories (Bar Harbor, 
Maine, USA). These mice express full-length ApoB-100 in their LDL particles and have 3-
fold higher plasma levels of ApoB100 than those in LDLR−/− mice. The mice were 
maintained under standard husbandry conditions and were supplied with food and water ad 
libitum. Intraperitoneal infection of the KO mice was started at 12-14 weeks of age and 
consisted of 100 µl of PBS containing 106 colony-forming units (CFU) of either 
BCGpMV262 or BCGpMV262(icl). Four mice from each group were sacrificed on days 10, 
14, 21 and 35 post-infection. The mice were euthanized and their spleens and lungs were 
excised. 
 
2.5.3 Culturing of BCG from the lungs and the spleen 
The dissected spleens were homogenized by pressing them through nylon mesh into 
PBS (1 ml) containing 0.05% Tween 20. The lungs were removed and homogenized 
mechanically in 1 ml of PBS containing 0.05% Tween 20. 100 µl of tissue suspension was 
used. Ten fold dilutions of these suspensions were plated on Middlebrook 7H10 agar for 
cultivation of the bacteria. CFUs were determined after 21 days of incubation at 37°C. 
 
2.5.4 Western blot  
Cell lysates of E. coli over-expressing ACP, LcrE, Icl and purified control 
(Chlamydial LcrH), ACP and LcrE proteins and concentrated C. pneumoniae elementary 
bodies were heated to 95°C for 5 min in sample buffer and separated by SDS-10% PAGE. 
The separated proteins were blotted onto a polyvinylidene difluoride membrane (SERVA 
Heidelberg, Germany). The membranes were blocked with PBS containing 5% skim milk and 
0.05% Tween 20 overnight at 4°C. 
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 In the case of Icl, membranes were probed with BCGpMV262(icl) immunized and 
control (BCGpMV262) mouse homogenized lungs (1:10 dilution in 5% skim milk and 0.05% 
Tween 20 containing PBS).  
In the case of ACP, membranes were probed with protein-immunized and control 
(alum only) mouse sera (1:50 dilution in 5% skim milk and 0.05% Tween 20 containing 
PBS). After washings, the filter was incubated with horseradish-peroxidase (HRP)-conjugated 
anti-mouse IgG (α-mouse IgG-HRP, Sigma) and the colour was developed using 
diaminobenzidine tetrahydrochloride (DAB, Sigma) with hydrogen peroxide in 10 mM Tris 
pH 7.5. 
 
2.5.5 ELISA test 
LcrE/ACP-specific antibodies in serial two-fold dilutions of the sera were detected by 
ELISA, using plates coated with recombinant LcrE/ACP protein (100 ng/well), and HRP-
conjugated secondary antibody was used for detection. The titres were determined at dilutions 
demonstrating an optical density (OD) higher than 0.1. 
 
2.5.6 Immunization with ACP protein 
Specific-pathogen-free 6-8-week-old, female BALB/c mice were obtained from 
Charles River Laboratories UK (Kent. England). Mice were maintained under standard 
husbandry conditions at the animal facility of the department and were given food and water 
ad libitum. Mice in groups of 5 were immunized subcutaneously at the tail base either with 
the purified ACP protein diluted in phosphate buffered saline (PBS) at a dose of 20 μg mixed 
with 25 μl Alum (Aluminum hydroxide Gel, Sigma) or with Alum only (control) in 150 μl 
volume 3 times at 3-week intervals. Mice were sacrificed 14 days after the last immunization.  
Blood was collected in heparinized capillaries from the retro-orbital plexus.  
 
2.5.7 Challenging the immunized and control mice  
The immunized mice were challenged with 4x105 inclusion forming units (IFU) of C. 
pneumoniae (CWL029, ATCC) in 25 μl PBS intranasally under pentobarbital sodium 
anaesthesia. At this time point serum samples were collected in heparinised capillaries by 
retro-orbital bleeding for testing the antibody production. At 7 days after infection the mice 
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were sacrificed. The lungs were removed and homogenized mechanically in 2 ml of sucrose-
phosphate-glutamic acid buffer for cultivation of bacteria.  
 
 
2.5.8 Culturing of C. pneumoniae from the lungs  
Lung homogenates from individual mice were centrifuged (10 min, 400 g), serial 
dilutions of the supernatants were inoculated onto HEp-2 cell monolayers and after 48 h 
culture cells were fixed with acetone and stained with monoclonal anti-C. pneumoniae 
antibody (DAKO Ltd. Ely, UK) and FITC-labelled anti-mouse IgG (Sigma). The number of 
C. pneumoniae inclusions was counted under a UV microscope, and the titre was expressed as 
IFU/ml. 
 
2.5.9 Determination of the toxicity of propionate  
 BCG bacteria carrying pMV262(icl) or the control plasmid (pMV262) were grown at 
37 °C in Middlebrook 7H9 (Difco) broth supplemented with OADC. Sodium proprionate 
(0.1%) and/or vitamin B12 (10µg/ml) were used where indicated. Optical density (600nm) was 
measured.  
 
2.6 Statistical analysis  
 Statistical analysis of the data was carried out with GraphPad Prism 5 software, using 
the Student t test. Differences were considered significant at p<0.05. 
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3. Results  
 
3.1 ACP as a possible new target molecule for immunization  
 
3.1.1 Over-expression of ATB/ACP proteins 
 Fig. 3 shows the over-expression of ATB and ACP proteins of M. tuberculosis and C. 
pneumoniae respectively. ATB is a protein consisting of 248 amino acids. Its calculated 
molecular mass is 28 kDa; because of the 6His and FLAG tags, our fusion protein is 4 kDa 
larger. ACP protein is smaller, it contains 226 amino acids. Its calculated molecular mass is 
25 kDa; it also contains the 6His and FLAG tags. The other protein parameters are 
summarized in Table 1. It can be seen that upon heat-induction a strong band appears at the 
indicated position (Fig. 3, lanes 2, 3, 5, 6). Since these proteins carry the 6His and FLAG tags, 
both tags can be exploited during purification. Fig. 3 shows that after heat-induction the 
strong over-expression occurred after 60 minutes in case of both proteins (Fig. 3, lane 3-ATB; 
lane 6-ACP). 
 
Fig. 3 10% SDS-PAGE analysis of E. coli extracts containing the overexpressed proteins  
Lanes 1, 4 show extract of E. coli culture without heat induction and lanes 2, 3 and 5, 6 show extracts 
of E. coli cultures with heat induction. Samples were taken at 30’ (lanes 2, 5) and 60’ (lanes 3, 6) after 
heat induction 
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Table 3. In silico comparison [77] of mycobacterial and chlamydial proteins 
 CpB0255 Rv0986 
Number of amino acids: 226 248 
Molecular weight:  24814.4 27373.1 
Theoretical pI:  6.65 5.63 
Total number of negatively charged 
residues (Asp + Glu): 
24 30 
Total number of positively charged 
residues (Arg + Lys):  
23 26 
Formula: C1092H1790N310O337S5 C1200H1954N346O374S5
Total number of atoms:  3534 3879 
The estimated half-life is (E. coli, in vivo): >10 hours >10 hours 
 
3.1.2 Purification of ACP protein  
 The purification results are presented in Fig. 4. The purification was carried out with 
the TALON CellThru Resin. ACP in the crude extract of heat induced E. coli and in the eluted 
fractions 3 and 4 appears as a strong band around MW 30 kDa position (Fig. 4, lanes 3, 4).  
 
 
Fig. 4 10% SDS-PAGE analysis of the purification process of ACP 
Lanes: 1 – the supernatant; 2 – wash buffer; 3–4 elution samples; MW – molecular weight marker 
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3.1.3. Level of ACP-specific IgG in the sera of immunized mice 
  Mice immunized with ACP protein mixed with Alum adjuvant responded with 
specific antibody production. ACP-specific IgG was detected by ELISA with a mean titre of 
44512. 
 
3.1.4 Protection against C. pneumoniae infection as measured by culturing of C. 
pneumoniae from the lungs 
 
  In order to find out the protective effect of ACP-specific immunity ACP-immunized 
mice were infected with C. pneumoniae. The mean number of recoverable bacteria from the 
lungs shows 30% reduction compared to the controls (data not shown). 
 
3.1.5 Western blot analysis 
 The immunogenicity of the purified protein in mice and the chlamydia–specificity of 
the produced antibodies were confirmed by Western blot (Fig. 5). After immunization with 
ACP protein, the mouse sera reacted only with a protein at the appropriate position in the 
concentrated C. pneumoniae preparation, with the purified ACP (Fig. 5B) and with ATB 
protein (Fig. 5A). This cross reactivity confirmed the epitope similarity between ACP and 
ATB proteins.  These proteins are virulence factors for intracellular bacteria; they are 
immunogenic and might be eligible components of a multi-subunit chlamydia/mycobacterium 
vaccine. The role of immune response needs further investigation. 
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Fig. 5  ACP-immunized and control mouse sera were tested in Western blot assay 
A. Overexpressed ATB (lanes 1, 3) and ACP (lanes 2, 4) containing cell lysates were probed with 
control mouse sera (lanes 1, 2) and with sera of ACP+Alum immunized mice (lanes 3, 4) 
B. Purified ACP protein (lanes 1, 3) and concentrated C. pneumoniae preparation (lanes 2, 4) were 
probed with control mouse sera (lanes 1, 2) and with sera of ACP+Alum immunized mice (lanes 3, 4) 
 
3.2 Modified BCG vaccine may improve the efficacy 
 The copy number of the pMV262(icl) in the BCG strain used for infection was 29. 
Fig. 6a shows the spleen weights of mice infected with BCG carrying Icl plasmids and the 
control. Twenty one days after infection, the spleens from mice that were infected with 
bacteria that carried the additional icl genes were three to four times larger than those of the 
controls (Fig. 6b).  
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Fig. 6 Spleen masses (g) after 10 (?), 14 ( ), 21 (?) and 35 (?) days of infection. The spleen 
weights were significantly higher in case of BCGpMV262(icl) than in BCGpMV262-infected mice 
(p\0.05) (a). Differences in spleen size. Spleens were removed from mice 21 days after infection with 
BCGpMV262 (lower) or BCGpMV262(icl) (upper) (b) 
 
 
 Bacteria with one copy of icl (the chromosomal gene) appeared in the spleen earlier 
and their clearance was faster than that from the lungs (Fig. 7). In the spleen, very few 
bacteria were found 21 days after infection and they had disappeared by the end of the 
experiment (35 days), whereas some bacteria were still detected in the lungs at this time. 
Bacteria containing the plasmid with the icl gene survived much longer and their yield was 8-
250 times higher. The CFUs were significantly higher in the samples from BCGpMV262(icl)-
infected mice than the control (p<0.05) (Fig. 7).  
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Fig. 7 Colony-forming units in 100 µl of tissue suspension from the spleen and lungs of infected 
animals after 10 (?), 14 ( ), 21 (?) and 35 (?) days of infection. The CFUs were significantly 
higher in the samples from BCGpMV262(icl) than in those from BCGpMV262-infected mice 
(p\0.005) 
 
 
Lungs from the BCG pMV262(icl)-immunized mice had increased antibody level against Icl 
as shown in Fig. 8.  
 
 
Fig. 8 BCGpMV262(icl) immunized and control mouse homogenized lungs were tested in Western 
blot assay. Purified control protein (chlamydial LcrH) (lanes 1, 3) and cell lysates from Icl-expressing 
E. coli (lanes 2, 4) were probed with BCGpMV262(icl) immunized (lanes 1, 2) and with 
BCGpMV262 immunized mouse homogenized lungs in 1:10 dilution (lanes 3, 4) 
  
We determined the toxic effect of propionate produced from the β-oxidation of odd-chain or 
branched-chain fatty acids. Fig. 9 shows that propionate was less toxic for bacteria carrying 
icl plasmids in vitro. Although vitamin-B12 increased the growth rate of both strains BCG 
pMV262(icl) multiplied much faster. 
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Fig. 9 Growth curves in the presence of sodium propionate (0.1 %) and with vitamin-B12 addition (10 
μg/ml). Growth was monitored by measuring the optical density of cultures using at least two 
independent experiments 
 
3.3 LcrE experiments 
 
3.3.1 Level of LcrE specific IgG in the sera in the immunized mice 
All of the mice immunized with LcrE protein mixed with Alum adjuvant, and most of 
the (7/10) mice immunized with p∆RCLcrE responded with LcrE specific antibody 
production. LcrE-specific IgG was detected by ELISA. There was a tendency for higher LcrE-
specific IgG level (p= 0.0625) in p∆RCLcrE-primed and LcrE protein boosted (Group 3) mice 
compared to non-primed mice (Group 1) (Fig. 10).  
 
Fig. 10 Two weeks after the last immunization sera were tested by LcrE-specific ELISA at dilution of 
1:100. LcrE-specific IgG was detected in pΔRC+LcrE protein immunized, in 2 × pΔRCLcrE-
immunized and in pΔRCLcrE-primed and LcrE protein boosted mice in contrast to the 2 × pΔRC-
immunized mice 
  30
 
Significant LcrE-specific IgG1 production was detected in the sera of LcrE protein 
immunized mice, however, the sera IgG2a level was low in mice without p∆RCLcrE priming 
(Fig. 11). Mice immunized with p∆RCLcrE plasmid only produced relatively higher level of 
LcrE-specific IgG2a antibody. Boosting the immune response in p∆RCLcrE-primed mice 
with LcrE protein raised not only the IgG1 but also the IgG2a level. The higher relative IgG2a 
level indicates a Th1-biased response in the case of DNA immunized mice irrespective of the 
nature of the booster inoculation. 
 
 
Fig. 11 LcrE-specific IgG1 and IgG2a levels in the sera of immunized and C. pneumoniae challenged 
mice. Isotype of LcrE-specific IgG in the sera of immunized mice was measured by ELISA. Symbols 
represent OD values measured with sera of individual mice. Sera were tested at a dilution of 1:800 for 
IgG1, and 1:100 for IgG2a 
 
 3.3.2 Western blot analysis of p∆RCLcrE-induced antibodies  
 The immunogenicity of the eukaryotic expression vector (p∆RCLcrE) in mice and the 
LcrE-specificity of the produced antibodies were confirmed by Western blot (Fig. 12) using 
PAGE-separated purified LcrE protein as antigen. Identity of purified LcrE protein was 
confirmed by MALDI-TOF mass spectrometry previously [38]. Sera of mice from Group 3 
(immunized 2 × p∆RCLcrE) reacted with the band at the position corresponding to the 
molecular weight of LcrE protein similarly to the sera of LcrE protein immunized-mice of the 
earlier published experiment [19]. 
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Fig. 12 Sera from immunized mice were tested in Western blot assay. Purified LcrE protein was 
probed with sera of 2 × pΔRCLcrE-immunized mice (lane 1), 2 × pΔRC-immunized mice (lane 2) and 
3 × LcrE protein+Alum immunized mice (lane 3) [66] 
 
3.3.3 Protection against C. pneumoniae infection as measured by culturing of C. 
pneumoniae from the lungs 
 To find out whether lcrE applied in DNA vaccine can induce protective immune 
response against C. pneumoniae infection, C. pneumoniae titres in the lungs of immunized 
and control mice were compared. The reduction in C. pneumonia burden in the lungs was 
37% in mice immunized with LcrE protein mixed with Alum adjuvant (Group 1); 55% in 
p∆RCLcrE-immunized mice (Group 2) and nearly 72% in p∆RCLcrE-primed and LcrE 
protein boosted mice (Group 3) when compared to p∆RC-immunized controls (Group 4) 
(Fig.13). This latter comparison showed significant difference with a p value of 0.01. 
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Fig. 13 C. pneumoniae titres in the lungs of LcrE-immunized mice after C. pneumoniae challenge. 
Lung homogenates were inoculated onto HEp-2 cell monolayers and chlamydial inclusions were 
detected by indirect immunofluorescence, using MOMP-specific monoclonal and FITC-labelled       
secondary antibodies. The titre of C. pneumoniae in the lungs of pΔRCLcrE+LcrE protein immunized 
mice was significantly (* p = 0.01) lower than in lungs of control (2 × pΔRC-immunized) mice 
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4. Discussion 
 
4.1 ABC transporter ATPases can be useful components of vaccines 
 As shown, we have chosen an important virulence factor of M. tuberculosis and its 
homologous protein from chlamydia, for cloning and expression. The immunogenicity of 
purified ACP protein and Chlamydia-specificity of the produced antibody were proved by 
Western blot. Low level of protection (albeit not a statistically significant) against C. 
pneumoniae infection was observed by culturing of C. pneumoniae from the lungs of ACP 
immunized mice. 
 The methods we applied are suitable for cloning, expression and purification of 
mycobacterial and chlamydial proteins, enabling immunological studies to identify vaccine 
candidates that would be eligible components of a multi-antigen vaccine which can induce an 
optimal protective immune response against these infections. 
 
4.2 Isocitrate lyase encoding plasmids in BCG cause increased survival in mice 
 Several vaccines against tuberculosis are currently undergoing clinical trials [78]. 
Some of them are subunit vaccines. Another approach is the use of recombinant BCG 
expressing antigens from M. tuberculosis. A recombinant M. smegmatis was recently shown 
to induce potent bactericidal immunity against M. tuberculosis. The Rv0467 (CAE55284.1) 
gene codes for Icl in M. tuberculosis H37Rv. In M. bovis BCG, the icl gene (GenBank 
accession no. CAL70492) differs in only one base and the amino acid composition is 
identical. The avirulent strain (M. tuberculosis H37Ra) has the same protein (GenBank 
accession no. ABQ72194). Sequence search was done using NCBI. Although we cloned icl 
from H37Rv, because of the identity the extended survival we observed should be due only to 
the increased copy number. The tricarboxylic acid cycle and the glyoxylate shunt together 
supply bacteria with both energy and precursors for carbohydrate synthesis from fatty acids. 
Icl has an important role in the methylcitrate cycle too where the processing of the toxic 
propionate occurs [79]. Thanks to the suggestion of an anonymous reviewer we determined 
the growth rate of the bacteria in the presence of propionate in vitro. Bacteria with increased 
icl copy multiplied much faster which can contribute to the increased number and survival in 
mice. Methycitrate cycle and the vitamin B12- dependent methylmalonyl pathway contribute 
to mycobacterial pathogenesis by the proper metabolism of propionate during growth on fatty 
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acids in the phagosome [80]. The,,lipid lunch’’ [81] results in long term survival. Being an 
enzyme expressed in the later stages of infection by M. tuberculosis, Icl may induce long-term 
protection if over-expressed from multicopy plasmids during BCG vaccination. In addition, 
the extended survival of this recombinant BCG itself may increase the efficacy of the vaccine. 
Western blot shows increased antibody response. It would be interesting to know the 
protective effect of this recombinant BCG. Because of the lack of biosafety level 3 facilities, 
we cannot perform these types of experiments. Recent results indicate functions for Icl which 
extend beyond fat metabolism. A novel metabolic route for carbohydrate metabolism was 
identified in which Icl is a key enzyme [82]. Gengenbacher et al. [83] showed that a reduced 
but constant intracellular ATP level is necessary in the adaptation of M. tuberculosis to non-
growing survival. Icl deficient nutrient-starved bacilli failed to reduce their intracellular ATP 
level and died. The mycobacterial cell wall is very rich in lipids: there are around 250 distinct 
enzymes involved in fatty acid metabolism, five times more than in E. coli [84]. We used 
ApoB100-only LDLR2/2 mice to gain an insight into the role of a high-fat diet on the course 
of infection, but no significant differences were observed with the different diets in our 
preliminary experiments (unpublished data). Further studies would be necessary to address 
this question. It was reported that high levels of cholesterol in the host diet significantly 
enhanced the M. tuberculosis in the lung [84, 85] and impaired immunity to this pathogen 
[86]. 
 
4.3 lcrE-containing DNA immunization 
 C. pneumoniae has generated huge attention during the last decade, not only as a 
respiratory pathogen but because of its possible association with a number of acute and 
chronic diseases, including atherosclerosis, Alzheimer’s disease and multiple sclerosis [38, 
87, 88, 89]. The true linkage and causality of C. pneumoniae infection in the development of 
chronic manifestations is poorly understood. Since antibiotics cannot fully inhibit chlamydial 
growth and because of the incomplete protection induced by natural infection, the 
development of an effective vaccine would be desirable to control the infections caused by 
this highly prevalent pathogen. With recent advances in chlamydial genomics and proteomics, 
a preference has developed for subunit vaccines. The multi-subunit approach to chlamydia 
vaccine will likely induce an effective long-lasting immunity. Structural proteins of type III 
secretion system are expected to be surface exposed and required for infection of host cells, 
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thus, these are attractive vaccine candidates to investigate [37, 90, 91, 92]. Protective effect of 
LcrE-specific immunity against C. pneumoniae infection in animal models has been studied. 
The results of our published experiments [66] are in agreement with previous reports [65, 93] 
that LcrE protein is an antigen with considerable potential as a vaccine subunit and in this 
study we confirmed that this antigen has protective effect formulated as a DNA vaccine, too. 
In our present study we show that we cloned lcrE gene into a eukaryotic expression vector, 
and lcrE-DNA immunization induced protective response against C. pneumoniae infection 
similar to that evoked by a single LcrE protein immunization. Moreover, in a prime-boost 
regime, i.e. lcrE DNA/LcrE protein vaccination, the protective effect reached 72% in respect 
of lung bacterial burden. This level of protection is significant and comparable to that 
achieved by multiple subcutaneous injection of LcrE protein mixed with Alum adjuvant as 
published earlier [94]. Our findings are that p∆RCLcrE immunization induces an immune 
response shifted towards Th1 type pathway characterized by increased IgG2a production, and 
immunization with LcrE protein which generates an IgG1-dominated Th2 type response did 
not alter the DNA priming-polarized Th1 type response in DNA-primed and protein-boosted 
mice. Further experiments with improved immunization regimens or modified plasmid 
vectors are planned for inducing an increased level of antibody and/or cellular response 
potentially leading to better protection. 
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The following of our results are considered novel 
 
• ABC transporter ATPases can be useful components of vaccines, we showed that                 
 chlamydial ATPase induces protective immunity in mice 
 
• Isocitrate lyase encoding plasmids in BCG cause increased survival in mice, this                         
 recombinant BCG can be a more effective vaccine 
 
• lcrE-containing DNA immunization given as a priming and followed by a protein      
 booster significantly reduced the number of viable bacteria in the lungs of mice         
 after challenge with C. pneumoniae 
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Summary 
      Tuberculosis (TB) has troubled humankind throughout history. It has been a leading 
cause of death, and still is in low- and middle-income countries. TB is a classic example of 
airborne infection. The causative agent, Mycobacterium tuberculosis, is a very successful 
pathogen. One third of the human population is infected with this bacterium. WHO declared 
TB a public health emergency in 1993. The available vaccine, bacillus Calmette-Guérin 
(BCG) has variable (generally low) efficacy in different parts of the world and no new drugs 
were introduced in the last 40 years. Multidrug- and extensively drug-resistant (MDR and 
XDR, respectively) strains have developed. 
      Chlamydophila pneumoniae is an obligate intracellular human pathogen, which causes 
respiratory tract infections, i.e. pneumonia, bronchitis, pharingitis and sinusitis. 
Seroepidemiological studies show that C. pneumoniae is widespread and nearly everybody 
becomes infected with it during his life. C. pneumoniae can also cause chronic infections, 
which might lead to atherosclerosis and heart disease. It is suspected to have a role in the 
pathogenesis of Alzheimer disease and multiple sclerosis. These are the reasons why it is 
important to develop vaccine against C. pneumoniae infection. 
      Better vaccines and new therapeutic drugs could be a successful breakthrough against 
intracellular bacteria. 
      M. tuberculosis ABC transporter ATPase (Rv0986) as virulence factor, plays a role in 
mycobacterial pathogenesis by inhibiting phagosome-lysosome fusion. Thus, it could be a 
potential vaccine candidate. C. pneumoniae possesses a protein named CpB0255, which is 
homologous with the mycobacterial Rv0986. We cloned, over-expressed and purified these 
bacterial ABC transporter ATPase proteins to study their biological properties.The 
immunogenicity and protective effect of recombinant chlamydial ATPase protein combined 
with Alum adjuvant were investigated in mice. The immunization resulted in the reduction of 
the number of viable C. pneumoniae in the lungs after challenge. Our results confirm that 
chlamydial ATPase induces protective immunity in mice, and the produced antibody also 
recognized mycobacterial ATPase protein, which justifies the epitope homology between 
these proteins.  
      We studied the role of isocitrate lyase in the interaction between Mycobacterium bovis 
BCG and mice. 
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      ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J) mice were inoculated 
with M. bovis BCG harbouring plasmids carrying the gene for isocitrate lyase. The presence 
of ~29 times more copies of this gene resulted in a higher bacterial yield in the spleens and 
lungs of the infected mice. The spleen was 3-4 times heavier, and in the spleen the bacteria 
survived over 10 days longer than did the bacteria with the control plasmid. Propionate was 
less toxic for bacteria carrying icl plasmids in vitro. This recombinant BCG can be a possible 
vaccine candidate. 
      C. pneumoniae possess type III secretion system (TTSS), which allows them to secrete 
effector molecules into the inclusion membrane and the host cell cytosol. Low calcium 
response protein E (LcrE) is a part of TTSS. The gene of LcrE in a 6His-tagged form was 
cloned from C. pneumoniae CWL029, expressed and purified from Escherichia coli using the 
HIS-select TALON CellThru Resin, this gene was also cloned into a eukaryotic expression 
vector (pΔRC). One group of BALB/c mice received an intramuscular pΔRC inoculation then 
the mice were immunized with purified LcrE protein; the second group of mice was 
immunized two times with the recombinant plasmid (pΔRCLcrE), and the third group was 
primed with pΔRCLcrE inoculation then boosted with LcrE protein. LcrE-specific antibody 
response was induced by DNA immunization with a shift towards Th1 isotype pattern 
compared to protein-immunization, this shifting pattern was observed in plasmid primed then 
protein-boosted animals. DNA immunization given as a priming and followed by a protein 
booster significantly reduced the number of viable bacteria in the lungs after challenge with 
C. pneumoniae. These results confirm that immunization with pΔRCLcrE can be an effective 
part of a vaccination schedule against C. pneumoniae.
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Összefoglalás 
 A tuberkulózis (tbc) az emberiség egyik legrégebbi betegsége. A történelem során az 
egyik legtöbb halálesetet okozó betegség volt és továbbra is vezető halálok az elmaradott/ 
fejlődő országokban. A betegség okozója a Mycobacterium tuberculosis baktérium, mely 
cseppfertőzés útján jut az emberi szervezetbe. Földünk népességének 1/3-a tbc fertőzött. 
1993-ban a WHO a tbc-t globális veszélyforrássá minősítette. Az egyetlen használatban lévő 
védőoltás, a bacillus Calmette-Guérin (BCG) vakcina, melynek hatékonysága kérdéses, 
elsősorban miliáris tuberkulózis és a meningitis tuberculosa visszaszorításában nyújt 
védelmet. Az utóbbi 40 évben nem sikerült új, hatékony gyógyszert kifejleszteni. További 
problémát jelent a multidrog-rezisztens (MDR) és extenzíven drog-rezisztens (XDR) 
baktériumok megjelenése.  
  Chlamydophila pneumoniae egy obligát intracelluláris humán patogén, mely a 
pneumoniák és más légúti fertőzések (bronchitis, pharingitis, sinusitis) gyakori kórokozója. 
Szeroepidemiológiai vizsgálatok rámutattak, hogy a baktérium világszerte elterjedt és 
majdnem mindenki átesik a fertőzésen élete során. Képes krónikus fertőzéseket is okozni, 
melyek szívinfarktushoz és atherosclerosishoz vezethetnek. Feltételezik szerepét, asthma 
bronchiale, Alzheimer-kór és sclerosis multiplex kórképek kialakulásában. Ezek a tények 
megerősítik a C. pneumoniae által okozott fertőzések elleni vakcinák mielőbbi 
kifejlesztésének szükségességét.  
 Hatékonyabb vakcinák és új terápiás gyógyszerek fejlesztése sikeres áttörést jelentene 
az intracelluláris baktériumok elleni küzdelemben.  
 A M. tuberculosis ABC transzporter ATPáz (Rv0986) virulencia faktorként szerepet 
játszik a pathogenezis folyamatában, a fagoszóma-lizoszóma fúzió megakadályozásával. 
Ennek következtében potenciális vakcina jelölt lehet. C. pneumoniae rendelkezik ezen fehérje 
homológjával (CpB0255). Munkánk során klónoztuk, kifejeztettük és tisztítottuk ezeket a 
bakteriális ABC transzporter ATPáz fehérjéket, biológiai tulajdonságuk tanulmányozása 
céljából. 
Az immunogenitást és védőhatást, Alum adjuvánssal kombinált rekombináns chlamydiális 
ATPáz fehérjével vizsgáltuk egerekben. Az immunizálás eredményeként csökkent a tüdőből 
visszatenyésztett C. pneumoniae száma. Az eredmény azt bizonyítja, hogy a chlamydiális 
ATPáz immunvédelmet biztosít az egerekben és a termeltetett antitestek a mikobakteriális 
ATPáz fehérjét is felismerik, amely igazolja az epitóp homológiát ezen fehérjék között 
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 Tanulmányoztuk az izocitrát liáz enzim szerepét Mycobacterium bovis BCG és egerek 
közötti kölcsönhatásban. ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J) 
egereket oltottunk be M. bovis BCG baktériummal, mely plazmidon hordozza az Icl fehérjét 
kifejező génszakaszt. A 29-szer több kópiában jelenlevő gén magas baktérium hozamot 
eredményezett a fertőzött egerek tüdejében és lépében. A lépek 3-4-szer nagyobbak voltak, és 
az itt jelenlévő baktériumok túlélése, a kontroll plazmidot hordozó baktériumok túléléséhez 
képest, 10 nappal hosszabb volt. A propionát kevésbé volt toxikus azon baktériumok számára, 
melyek az icl gént hordozó plazmidot tartalmazták. Ez a rekombináns BCG lehetséges 
vakcina jelölt lehet a későbbiekben.  
 A C. pneumoniae hármas típusú szekréciós rendszerrel (TTSS) rendelkezik, mely 
lehetővé teszi a baktérium számára, hogy effektor fehérjéket juttasson a fertőzött sejt 
citoplazmájába. Az LcrE (Low calcium response protein E) fehérje ezen TTSS rendszer tagja. 
A 6His-tag-gel ellátott LcrE fehérje génjét, C. pneumoniae CWL029 DNS-ből klónoztuk. 
Escherichia coli baktériumban kifejeztettük. A fehérjéket HIS-select TALON CellThru Resin 
segítségével tisztítottuk. Az LcrE fehérjét kifejező gént, eukarióta expressziós vektorba 
(pΔRC) is klónoztuk. BALB/c egerek első csoportját intramuszkulárisan oltottuk  pΔRC-vel, 
majd immunizáltuk tisztított LcrE fehérjével; az egerek második csoportját kétszer 
immunizáltuk a rekombináns plazmiddal (pΔRCLcrE), az egerek harmadik csoportját pedig 
pΔRCLcrE-vel  „primingoltuk” és LcrE emlékeztető oltást adtunk.  
A DNS immunizálás LcrE-specifikus ellenanyag termelést váltott ki, amely a Th1 típusú 
immunválasz felé tolódott el a fehérje immunizáláshoz képest. Ez a változás megfigyelhető 
volt abban a csoportban is, mely először DNS oltást kapott és utána fehérjét. A DNS 
immunizálás eredményeként, mely „primingból” és emlékeztető oltásból állt, csökkent a 
tüdőből visszatenyésztett C. pneumoniae száma. Ezek az eredmények megerősítik, hogy a 
pΔRCLcrE, rekombináns plazmiddal való immunizálás eredményes lehet a C. pneumoniae 
fertőzés ellen. 
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Abstract We studied the role of isocitrate lyase in the
interaction between Mycobacterium bovis BCG and mice.
ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/
J) mice were inoculated with M. bovis BCG harbouring
plasmids carrying the gene for isocitrate lyase. The pres-
ence of *29 times more copies of this gene resulted in a
higher bacterial yield in the spleens and lungs of the
infected mice. The spleen was 3–4 times heavier, and in the
spleen the bacteria survived over 10 days longer than did
the bacteria with the control plasmid. Propionate was less
toxic for bacteria carrying icl plasmids in vitro. This
recombinant BCG can be a possible vaccine candidate.
Keywords BCG  Immunization  Isocitrate lyase 
M. tuberculosis
Introduction
More than one-third of the world’s population is infected
with tuberculosis (TB) bacilli. Mycobacterium tuberculosis
is a very successful pathogen. There were an estimated 9.4
million new cases of TB in 2009 and an estimated 1.7
million deaths (including 380 000 people with HIV),
making this disease one of the world’s most significant
infectious killers. Millennium Development Goal 6 is that
the incidence of TB should be falling by 2015 [1].
Although Mycobacterium bovis BCG is the only
approved vaccine used for the prevention of TB in humans,
the protective efficacy of the BCG vaccine varies widely in
different parts of the world, reaching a maximum of 78 %
[2]. Most current efforts to improve the level of protec-
tive immunity provided by BCG include the develop-
ment of recombinant BCG vaccines expressing different
antigens [3].
The survival of M. tuberculosis in infected macrophages
requires the activity of isocitrate lyase (Icl), a key enzyme
in the glyoxylate cycle. The glyoxylate shunt permits the
effective utilization of two-carbon compounds, such as
acetate (from the b-oxidation of fatty acids), to satisfy
carbon requirements [4]. The glyoxylate cycle is required
for the virulence of other bacteria and fungi [5, 6]. In
mycobacteria, Icl has a dual role in the metabolism of fatty
acids. It participates in the methylcitrate cycle too [7].
b-oxidation of odd-chain or branched-chain fatty acids
results in the production of propionyl-CoA which is toxic
for bacteria and fungi [8, 9]. Propionyl-CoA is metabolised
in the methylcitrate cycle. The other way to use up pro-
pionyl-CoA is the methylmalonyl pathway. It requires a
vitamin-B12-derived cofactor [10].
A key to the intracellular survival of M. tuberculosis is
its ability to prevent the fusion of phagosomes containing
the internalized bacterium with the lysosomal system of the
host cell. The addition of certain exogenous fatty acids
modulates phagosome maturation, resulting in the killing
of pathogenic bacteria, whereas other fatty acids stimulate
pathogen growth [11]. Thus the role of lipids is
multifaceted.
We used ApoB100-only LDLR-/- mice to determine
the survival of M. bovis BCG carrying plasmids coding for
Icl. This double-knock-out (KO) mouse strain produces
only apolipoprotein-B-100 and is deficient in low-density
lipoprotein (LDL) receptors. This mouse model has a lipid
profile similar to that in most humans with atherosclerosis.
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Extended BCG survival is observed if the bacteria carry
plasmids with the gene coding for Icl. We assume that this
increased survival can result in more effective protection.
Materials and methods
Bacterial strains and growth conditions
Mycobacterium bovis BCG was grown in Middlebrook
7H9 broth or 7H10 agar (Difco Laboratories, Detroit, MI,
USA) enriched with 10 % Middlebrook OADC (oleic acid/
albumin/dextrose/catalase) (Difco) and 0.05 % Tween 80
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) with
the appropriate antibiotic. Escherichia coli DH5a was used
for plasmid preparation.
Plasmid construction
We constructed pMV262(icl), which carries icl after the
mycobacterial icl promoter (GenBank accession no.
CAE55284.1) in pMV262 [12]. I1 50-ACT ATC TAG ATC
CGC AGG ACG TCG A-3 and I2 50-GTA AGC TTC AGA
CTA GTG GAA CTG G-30 primers were used to synthetize
icl with M. tuberculosis H37Rv chromosomal DNA as
template. Primers were planned by using the sequence of
H37Rv [13]. The PCR amplification conditions were as
recommended by the manufacturer, with a GeneAmp II
(Applied Biosystems, Foster City, CA, USA) thermocycler
with Advantage GC cDNA polymerase (BD Biosciences
Clontech, Mountain View, CA, USA). The amplified DNA
was cut with XbaI and HindIII and inserted into pMV262
opened with the same enzymes.
Gene copy number determination
The high pure PCR template preparation kit (Roche
Diagnostic GmbH, Mannheim, Germany; Cat. No.:
1796828) was used for DNA extraction. Each DNA sample
was analysed in triplicate. The reaction volume was 15 ll,
containing 3 ll of DNA, 1 lmol/l of each of the primers
(2 ll), 7.5 ll of reaction buffer (IQTM 2X Supermix, Bio-
Rad Laboratories, Hercules, CA, USA) 0.6 ll of EVA-
Green (20 9 EVAGreenTM Biotium Inc., Hayward, CA,
USA) and 1.9 ll of distilled water. We used the forward
primer 50-AGC GCA TAT GTC TGT CGT CGG-30 and
reverse primer 50-GTA AGC TTC AGA CTA GTG GAA
CTG G-30 for icl. The reference gene (GenBank accession
no. O53899) primer set was 50 TGG CAT ATG AAC CGG
CAA CCT ATC 30 and 50 GAG GAT CCT CAT TCA TAG
GAC GTG 30. The primer sets have very similar efficien-
cies. A BIO-RAD CFX 96 instrument (Bio-Rad, Hercules,
CA, USA) was used for quantitation. The PCR conditions
were initial denaturation at 95 C for 10 min, followed by
35 cycles of denaturation (94 C for 20 s), annealing
(55 C for 30 s) and extension (68 C for 45 s). The
emitted fluorescence was measured after the extension step.
Quantitation was performed by online monitoring for
identification of the exact time point at which the loga-
rithmic linear phase could be distinguished from the
background (crossing point). The gene copy number was
calculated by the DCt method with Bio-Rad CFX Manager
1.1 Gene Expression software.
Electroporation of M. bovis BCG
Competent M. bovis BCG prepared in 10 % glycerol was
transformed with pMV262 or pMV262(icl) by electropor-
ation with a Gene Pulsar (Bio-Rad, Mu¨nchen, Germany)
set at 2.5 kV and 25 lF, and with the pulse controller
resistance set at 1,000 X [14, 15]. Transformed BCG was
selected on Middlebrook 7H10 agar plates supplemented
with 30 lg/ml kanamycin.
Mouse experiments
We used ApoB100-only LDLR-/- (B6;129S-ApoBtm2Sgy
Ldlrtm1Her/J; 16 females per group and their weight ranged
from 25 to 30 g) with the genetic background of a mixture
of C57BL/6 and a particular 129 strain from Jackson
Laboratories (Bar Harbor, Maine, USA). These mice
express full-length ApoB-100 in their LDL particles and
have threefold higher plasma levels of ApoB100 than those
in LDLR-/- mice. The mice were maintained under stan-
dard husbandry conditions and were supplied with food and
water ad libitum. Intraperitoneal infection of the KO mice
was started at 12–14 weeks of age and consisted of 100 ll
of PBS containing 106 colony-forming units (CFU) of
either BCGpMV262 or BCGpMV262(icl). Four mice from
each group were sacrificed on days 10, 14, 21 and 35 post-
infection. The mice were euthanized and their spleens and
lungs were excised.
All experiments complied with the University of Szeged
guidelines for the use of laboratory animals.
Culturing of BCG from the lungs and the spleen
The dissected spleens were homogenized by pressing them
through nylon mesh into PBS (1 ml) containing 0.05 %
Tween 20. The lungs were removed and homogenized
mechanically in 1 ml of PBS containing 0.05 % Tween 20.
100 ll of tissue suspension was used. Tenfold dilutions of
these suspensions were plated on Middlebrook 7H10 agar
for cultivation of the bacteria. CFUs were determined after
21 days of incubation at 37 C.
4722 Mol Biol Rep (2013) 40:4721–4725
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Western blot
Cell lysates of E. coli over-expressing Icl and purified
control (chlamydial LcrH) [16] protein were heated to
95 C for 5 min in sample buffer and separated by SDS-
10 % PAGE. The separated proteins were blotted onto a
polyvinylidene difluoride membrane (SERVA Heidelberg,
Germany). The membranes were blocked with PBS con-
taining 5 % skim milk and 0.05 % Tween 20 overnight at
4 C. Membranes were probed with BCGpMV262(icl)
immunized and control (BCG pMV262) mouse homoge-
nized lungs (1:10 dilution in 5 % skim milk and 0.05 %
Tween 20 containing PBS). After washings, the filter was
incubated with HRP-conjugated anti-mouse IgG for 2 h,
and the colour was developed using diaminobenzidine
tetrahydrochloride (DAB, Sigma) with hydrogen peroxide
in 10 mM Tris pH 7.5 according to the manufacturer’s
instructions.
Statistical analysis
Statistical analysis of the data was carried out with
GraphPad Prism 5 software, using the Student t test. Dif-
ferences were considered significant at P \ 0.05.
Determination of the toxicity of propionate
Bacteria carrying pMV262(icl) or the control plasmid
(pMV262) were grown at 37 C in Middlebrook 7H9
(Difco) broth supplemented with OADC. Sodium propio-
nate (0.1 %) and/or vitamin B12 (10 lg/ml) were used
where indicated. Optical density (600 nm) was measured.
Results are representative of two experiments.
Results
The copy number of the pMV262(icl) in the BCG strain
used for infection was 29. Figure 1a shows the spleen
weights of mice infected with BCG carrying Icl plasmids
and the control. Twenty one days after infection, the
spleens from mice that were infected with bacteria that
carried the additional icl genes were three to four times
larger than those of the controls (Fig. 1b).
Bacteria with one copy of icl (the chromosomal gene)
appeared in the spleen earlier and their clearance was faster
than that from the lungs (Fig. 2). In the spleen, very few
bacteria were found 21 days after infection and they had
disappeared by the end of the experiment (35 days),
whereas some bacteria were still detected in the lungs at
this time. Bacteria containing the plasmid with the icl gene
survived much longer and their yield was 8–250 times
higher. The CFUs were significantly higher in the samples
from BCGpMV262(icl)-infected mice than the control
(P \ 0.005) (Fig. 2). Lungs from the BCG pMV262(icl) -
immunized mice had increased antibody level against Icl as
shown in Fig. 3.
We determined the toxic effect of propionate produced
from the b-oxidation of odd-chain or branched-chain fatty
acids. Figure 4 shows that propionate was less toxic for
bacteria carrying icl plasmids in vitro. Although vitamin-
B12 increased the growth rate of both strains BCG
pMV262(icl) multiplied much faster.
Discussion
Several vaccines against tuberculosis are currently under-
going clinical trials [17]. Some of them are subunit vac-
cines. Another approach is the use of recombinant BCG
expressing antigens from M. tuberculosis. A recombinant
M. smegmatis was recently shown to induce potent bacte-
ricidal immunity against M. tuberculosis [18].
Fig. 1 Spleen masses (g) after 10 ( ), 14 ( ), 21 ( ) and 35 ( ) days
of infection. The spleen weights were significantly higher in case of
BCGpMV262(icl) than in BCGpMV262-infected mice (P \ 0.05).
a Differences in spleen size. Spleens were removed from mice
21 days after infection with BCGpMV262 (lower) or BCGpMV262
(icl) (upper) (b)
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The Rv0467 (CAE55284.1) gene codes for Icl in
M. tuberculosis H37Rv. In M. bovis BCG, the icl gene
(GenBank accession no. CAL70492) differs in only one
base and the amino acid composition is identical. The
avirulent strain (M. tuberculosis H37Ra) has the same
protein (GenBank accession no. ABQ72194). Sequence
search was done using NCBI. Although we cloned icl from
H37Rv, because of the identity the extended survival we
observed should be due only to the increased copy number.
The tricarboxylic acid cycle and the glyoxylate shunt
together supply bacteria with both energy and precursors
for carbohydrate synthesis from fatty acids. Icl has an
important role in the methylcitrate cycle too where the
processing of the toxic propionate occurs [7]. Thanks to
the suggestion of an anonymous reviewer we determined
the growth rate of the bacteria in the presence of propionate
in vitro. Bacteria with increased icl copy multiplied much
faster which can contribute to the increased number and
survival in mice. Methycitrate cycle and the vitamin B12-
dependent methylmalonyl pathway contribute to myco-
bacterial pathogenesis by the proper metabolism of propi-
onate during growth on fatty acids in the phagosome [10].
The ,,lipid lunch’’ [19] results in long term survival. Being
an enzyme expressed in the later stages of infection by M.
tuberculosis, Icl may induce long-term protection if over-
expressed from multicopy plasmids during BCG vaccina-
tion. In addition, the extended survival of this recombinant
BCG itself may increase the efficacy of the vaccine.
Western blot shows increased antibody response. It would
be interesting to know the protective effect of this recom-
binant BCG. Because of the lack of biosafety level 3
facilities, we cannot perform these types of experiments.
Recent results indicate functions for Icl which extend
beyond fat metabolism. A novel metabilc route for carbo-
hydrate metabolism was identified in which Icl is a key
enzyme [20]. Gengenbacher et al. [21] showed that a
reduced but constant intracellular ATP level is necessary in
the adaptation of M. tuberculosis to non-growing survival.
Icl deficient nutrient-starved bacilli failed to reduce their
intracellular ATP level and died.
The mycobacterial cell wall is very rich in lipids: there
are around 250 distinct enzymes involved in fatty acid
metabolism, five times more than in E. coli [13]. We used
ApoB100-only LDLR2/2 mice to gain an insight into the
role of a high-fat diet on the course of infection, but no
significant differences were observed with the different
diets in our preliminary experiments (unpublished data).
Fig. 2 Colony-forming units in
100 ll of tissue suspension from
the spleen and lungs of infected
animals after 10 ( ), 14 ( ), 21
( ) and 35 ( ) days of infection.
The CFUs were significantly
higher in the samples from
BCGpMV262(icl) than in those
from BCGpMV262-infected
mice (P \ 0.005)
Fig. 3 BCGpMV262(icl) immunized and control mouse homoge-
nized lungs were tested in Western blot assay. Purified control protein
(chlamydial LcrH) (lanes 1, 3) and cell lysates from Icl expressing
E. coli (lanes 2, 4) were probed with BCGpMV262(icl) immunized
(lanes 1, 2) and with BCGpMV262 immunized mouse homogenized
lungs in 1:10 dilution (lanes 3, 4)
Fig. 4 Growth curves in the presence of sodium propionate (0.1 %)
and with vitamin-B12 addition (10 lg/ml). Growth was monitored by
measuring the optical density of cultures using at least two
independent experiments
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Further studies would be necessary to address this question.
It was reported that high levels of cholesterol in the host
diet significantly enhanced the M. tuberculosis in the lung
[22, 23] and impaired immunity to this pathogen [24].
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Better vaccines and new therapeutic drugs could be a successful breakthrough
against intracellular bacteria. M. tuberculosis ABC transporter ATPase (Rv0986)
plays a role in mycobacterial virulence by inhibiting phagosome-lysosome fusion.
Thus, it could be a potential vaccine candidate. C. pneumoniae another important
intracellular bacterium possesses a protein named CpB0255, which is homologous
with the mycobacterial Rv0986. The aim of this study was the cloning, over-expres-
sion and purification of CpB0255 ABC transporter ATPase protein to study its biolog-
ical properties. The immunogenicity and protective effect of recombinant chlamydial
ATPase protein combined with Alum adjuvant were investigated in mice. The immu-
nization resulted in the reduction of the number of viable C. pneumoniae in the lungs
after challenge. Our results confirm that chlamydial ATPase induces protective immu-
nity in mice.
Keywords: ABC transporter ATPase, CpB0255, over-expression
Introduction
The investigation of intracellular bacteria is a very important research area.
The survival and spread of these bacteria depend on their ability to replicate inside
the eukaryotic cell. The similar life habit might be realized through the homolo-
gous proteins. The family Chlamydiaceae includes obligate intracellular bacteria,
1217-8950/$20.00 © 2013 Akadémiai Kiadó, Budapest
Acta Microbiologica et Immunologica Hungarica, 60 (1), pp. 11–20 (2013)
DOI: 10.1556/AMicr.60.2013.1.2
* Corresponding author; E-mail: szabo.agnes.mira@gmail.com
which have a unique two-phased developmental cycle. The virulent elementary
body, which is protected against the environmental effects, is able to transform
into metabolically active reticulate body [1]. There is a persistent phase where
chlamydiae are able to remain alive for a long time. Supposedly, the persistent
phase may have an important role in chronic infection [2].
The best known members of this family are the human genital and ocular
pathogen Chlamydia trachomatis and the respiratory pathogen Chlamydophila
pneumoniae (C. pneumoniae). We examined the latter C. pneumoniae. This bacte-
rium causes upper respiratory infections and pneumonia; and is associated with
asthma, chronic bronchitis, atherosclerosis, acute myocardial infarction and Alz-
heimer’s disease [3–7]. It has been shown that infections caused by intracellular
bacteria could be challenging for microbiologists, moreover, the fight against tu-
berculosis (TB) could be a good example for failure of the conventional therapeu-
tic approaches. TB, caused by Mycobacterium tuberculosis (M. tuberculosis), is
still an enormous problem all over the world [8, 9]. According to the 2009 data of
the WHO, 10 million new cases were detected and nearly 2 million victims are
claimed by TB that year [8].
No new anti-TB drugs have been introduced in the past 40 years, neverthe-
less, their development is becoming increasingly important to face the new chal-
lenges posed by multidrug-resistant and extensively drug-resistant strains [10].
The efficiency of BCG vaccine is not adequate [11, 12].
These rankling numbers show that new effective drugs and immunization
strategies are needed to overcome this problem. More efficient vaccination against
C. pneumoniae and M. tuberculosis would be a great step in the prevention and
treatment of these infections. ABC transporter ATPase, encoded by Rv0986 gene
of M. tuberculosis H37Rv strain, is involved in cell adhesion and entry [13], and
plays a part in the inhibition of phagosome-lysosome fusion [14]. The expression
of ATPase protein gene is up-regulated by at least 20-fold in mycobacterium dur-
ing infection [15]. These are the reasons why it can be a suitable vaccine candi-
date. The proteins which are involved in bacterial cell invasion might be similar in
different intracellular bacteria. C. pneumoniae has a homologous ATPase protein,
encoded by CpB0255 gene. The purpose of this study was the cloning, over-ex-
pression and purification of chlamydial ABC transporter ATPase protein; exami-
nation of the immunogenicity and the protective ability of subcutaneous recombi-
nant protein vaccination with chlamydial ABC transporter ATPase against C.
pneumoniae infection in mice.
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Experimental procedures
Bacterial strains
C. pneumoniae CWL029 (ATCC), Escherichia coli DH5a and E. coli
HB101 (pGP1-4)
Plasmid constructions
A 681 bp fragment containing the analogous ABC transporter ATPase
(ACP) (GeneID: 33241335; Locus tag: CpB0255) gene from C. pneumoniae was
amplified by PCR, using the following primers: AB3 5’ GGG CAT ATG TCC
TTA CTT ATA GAA G 3’ and AB4 5’ AAC GGA TCC AGA GGG AGT GTT
TTC 3’, and C. pneumoniae CWL029 DNA as template. PCR was performed in a
GeneAmp II (AppliedBiosystems, Foster City, CA, USA) thermocycler with Ad-
vantage GC cDNA polymerase (Clontech, Mountain View, CA, USA) and the
amplification conditions were set as recommended by the manufacturer. The am-
plified DNA was digested with NdeI and BamHI and inserted into p6HisF-11d
(icl) [16] by digesting it with the same enzymes and replacing the icl gene. The re-
sulted plasmid was pATB and pACP.
Expression of ACP
For over-expression, E. coli HB101 (pGP1-4) cells carrying the pACP
plasmids were grown and treated according to the method of Tabor and Richard-
son [17]. Briefly, cells containing the plasmids were grown at 32°C in LB medium
in the presence of the required antibiotics (ampicillin and kanamycin). Over-ex-
pression of proteins was induced by shifting the temperature to 42°C for 20 min.
After induction, the temperature was shifted down to 37°C for an additional 30
min or longer, cells were harvested by centrifugation and cell pellets were frozen.
Purification of ACP protein
Cell lysates were prepared by resuspending the frozen cell pellets in lysis
buffer (50 mM sodium phosphate, 300 mM sodium chloride, pH 7.0) containing
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protease inhibitor cocktail (Sigma) and lysozime (Sigma) (0.75 mg/ml). Bacteria
were opened by sonication. After centrifugation, ACP protein was purified from
the supernatant using the TALON CellThru Resin (Clontech), following the ven-
dor’s instructions.
Protein detection
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
was performed according to Laemmli [18]. Gels were stained with Coomassie
brillant blue [19].
Western blot
Cell lysates of E. coli over-expressing ACP, purified ACP protein and con-
centrated C. pneumoniae elementary bodies (prepared as described earlier [20])
were heated to 95°C for 5 min in sample buffer, and the proteins were separated by
SDS-10% PAGE. The separated proteins were blotted onto a polyvinylidene
difluoride membrane (SERVA Heidelberg, Germany). The membranes were
blocked with PBS containing 5% skim milk and 0.05% Tween 20 overnight at
4°C. Membranes were probed with protein-immunized and control (alum only)
mouse sera (1:50 dilution in 5% skim milk and 0.05% Tween 20 containing PBS).
After washings, the filter was incubated with HRP-conjugated anti-mouse IgG,
and the colour was developed using diaminobenzidine tetrahydrochloride (DAB,
Sigma) with hydrogen peroxide in 10 mM Tris pH 7.5.
ELISA test
ACP-specific antibodies in serial twofold dilutions of the sera were de-
tected by ELISA, using plates coated with recombinant ACP protein (100
ng/well), and horseradish-peroxidase (HRP)-conjugated secondary antibody
(a-mouse IgG-HRP, Sigma) was used for detection. The titres were determined at
dilutions demonstrating an optical density (OD) higher than 0.1.
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Immunization and challenge
Specific-pathogen-free 6–8-week-old, female BALB/c mice were obtained
from Charles River Laboratories UK (Kent, England). Mice were maintained un-
der standard husbandry conditions at the animal facility of the department and
were given food and water ad libitum. Mice in groups of 5 were immunized subcu-
taneously at the tail base either with the purified ACP protein diluted in phosphate
buffered saline (PBS) at a dose of 20 µg mixed with 25 µl Alum (Aluminum hy-
droxide Gel, Sigma) or with Alum only (control) in 150 µl volume 3 times at
3-week intervals. Mice were sacrificed 14 days after the last immunization.
Blood was collected in heparinized capillaries from the retro-orbital
plexus.
Challenging the immunized and control mice
The immunized mice were challenged with 4 × 105 inclusion forming units
(IFU) of C. pneumoniae (CWL029, ATCC) in 25 µl PBS intranasally under
pentobarbital sodium anaesthesia. At this time point serum samples were collected
in heparinised capillaries by retro-orbital bleeding for testing the antibody produc-
tion. At 7 days after infection the mice were sacrificed. The lungs were removed
and homogenized mechanically in 2 ml of sucrose-phosphate-glutamic acid buffer
for cultivation of bacteria.
All animal experiments complied with the University Guidelines for the
Use of Laboratory Animals.
Culturing of C. pneumoniae from the lungs
Lung homogenates from individual mice were centrifuged (10 min, 400 g),
serial dilutions of the supernatants were inoculated onto HEp-2 cell monolayers
and after 48 h culture cells were fixed with acetone and stained with monoclonal
anti-C. pneumoniae antibody (DAKO Ltd. Ely, UK) and FITC-labelled anti-
mouse IgG (Sigma). The number of C. pneumoniae inclusions was counted under
a UV microscope, and the titre was expressed as IFU/ml.
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Results and Discussion
Protein over-expression
Figure 1 shows the over-expression of ACP protein of C. pneumoniae.
ACP protein contains 226 amino acids. Its calculated molecular mass is 25
kDa; it also contains the 6His and FLAG tags. It can be seen that upon heat-induc-
tion a strong band appears at the indicated position (Fig. 1, lanes 1, 2, 3). Since
these proteins carry the 6His and FLAG tags, both tags can be exploited during pu-
rification. Figure 1 shows that after heat-induction the strong over-expression oc-
curred after 60 minutes in case of the protein (Fig. 1, lane 3-ACP).
Purification of ACP protein
The purification results are presented in Figure 2. The purification was car-
ried out with the TALON CellThru Resin. ACP in the crude extract of heat in-
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Figure 1. 10% SDS-PAGE analysis of E. coli extracts with cloned ACP gene
Lane 1 shows extract of E. coli culture without heat induction and lanes 2, 3 show extracts of E. coli
cultures with heat induction. Samples were taken at 30’ (lane 2) and 60’ (lane 3) after heat induction
MW 1 2 3
C. pneumoniae
ABC transporter
ATPase
duced E. coli and in the eluted fractions 3 and 4 appears as a strong band at MW 30
kDa position (Fig. 2, lanes 3, 4).
Level of ACP-specific IgG in the sera of immunized mice
Mice immunized with ACP protein mixed with Alum adjuvant responded
with specific antibody production. ACP-specific IgG was detected by ELISA with
a mean titre of 44512.
Protection against C. pneumoniae infection as measured
by culturing of C. pneumoniae from the lungs
In order to find out the protective effect of ACP-specific immunity ACP-
immunized mice were infected with C. pneumoniae. The mean number of recov-
erable bacteria from the lungs show 30% reduction compared to the controls (data
not shown).
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Figure 2. 10% SDS-PAGE analysis of the purification process of ACP
Lanes: 1 – the supernatant; 2 – wash buffer; 3–4 elution samples; MW – molecular weight marker
1 2 3 4 MW
kDa
116
66.2
45
35
ACP
protein
25
Western blot analysis
The immunogenicity of the purified protein in mice and the chlamydia-
specificity of the produced antibodies were confirmed by Western blot (Fig. 3).
After immunization with ACP protein, the mouse sera reacted only with a protein
at the appropriate position in the concentrated C. pneumoniae preparation, with
the purified ACP (Fig. 3B).
This protein is a virulence factor for intracellular bacteria; it is immuno-
genic and might be eligible components of a multi-subunit chlamydia vaccine.
The role of immune response needs further investigation.
Conclusion
As shown, we have chosen an important virulence factor of C. pneumoniae
for cloning and expression. The immunogenicity of purified ACP protein and
Chlamydia-specificity of the produced antibody were proved by Western blot.
Low level of protection (albeit not a statistically significant) against C.
pneumoniae infection was observed by culturing of C. pneumoniae from the lungs
of ACP immunized mice.
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Figure 3. ACP-immunized and control mouse sera were tested in Western blot assay
A) Cell lysates from ACP-overexpressing E. coli were probed with control mouse sera (lane 1)
and with sera of ACP+Alum immunized mice (lane 2)
B) Purified ACP protein (lanes 1, 3) and concentrated C. pneumoniae preparation (lanes 2, 4) were
probed with control mouse sera (lanes 1, 2) and with sera of ACP+Alum immunized mice
(lanes 3, 4)
The methods we applied are suitable for cloning, expression and purifica-
tion of mycobacterial and chlamydial proteins, enabling immunological studies to
identify vaccine candidates that would be eligible components of a multi-antigen
vaccine which can induce an optimal protective immune response against these in-
fections.
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Chlamydophila pneumoniae is an obligate intracellular human pathogen,
which causes acute respiratory tract infections and can also cause chronic infections.
C. pneumoniae possess type III secretion system (TTSS), which allows them
to secrete effector molecules into the inclusion membrane and the host cell cytosol.
Low calcium response protein E (LcrE) is a part of TTSS. The gene of LcrE in a
6His-tagged form was cloned from C. pneumoniae CWL029, expressed and purified
from Escherichia coli using the HIS-select TALON CellThru Resin, this gene was
also cloned into a eukaryotic expression vector (pRC). One group of BALB/c mice
received an intramuscular pRC inoculation then the mice were immunized with puri-
fied LcrE protein; the second group of mice was immunized two times with the recom-
binant plasmid (pRCLcrE), and the third group was primed with pRCLcrE inocula-
tion then boosted with LcrE protein. LcrE-specific antibody response was induced by
DNA immunization with a shift towards Th1 isotype pattern compared to protein-im-
munization, this shifting pattern was observed in plasmid primed then protein-boosted
animals. DNA immunization given as a priming and followed by a protein booster sig-
nificantly reduced the number of viable bacteria in the lungs after challenge with
C. pneumoniae. These results confirm that immunization with pRCLcrE can be an
effective part of a vaccination schedule against C. pneumoniae.
Keywords: LcrE protein, Chlamydophila pneumoniae, DNA immunization
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Introduction
Chlamydophila pneumoniae (C. pneumoniae) is an obligate intracellular,
Gram-negative bacterium, which is one of the most common human pathogens
that cause acute infections like pneumonia, bronchitis and pharyngitis. According
to the seroepidemiological studies, 50–70% of adult population worldwide is se-
ropositive to C. pneumoniae [1]. Respiratory infections caused by C. pneumoniae
are often mild with no symptoms, or only symptom of extended cough [2], and in
most cases they probably remain undiagnosed. An asymptomatic and thereby un-
treated chlamydial infection may become persistent and lead to chronic condi-
tions. Also, incomplete immunity after natural infection facilitates repeated infec-
tions that may exacerbate pathology and chronic diseases. The association of C.
pneumoniae with chronic human diseases was first shown in seroepidemiological
studies, which demonstrated the association of antibodies to C. pneumoniae with
acute myocardial infarction [3]. Later, the association of the infection with other
chronic diseases, such as asthma and chronic bronchitis, has been suggested [4].
The seroepidemiological data linking C. pneumoniae infection to coronary artery
disease (CAD) have also been supported by detection of antigens by immuno-
cytochemistry or nucleic acids of the organism by PCR in the affected tissues
[5–7]. Yet, the timing of C. pneumoniae infection and development of arterioscle-
rosis is poorly understood [8–12]. Although acute chlamydial infections are cur-
able with antibiotics, the antimicrobial therapy, used in treatment of acute infec-
tions, may not be effective in resolving the infection in the associated chronic con-
ditions [13, 14]. Therefore, vaccination has been suggested to be an effective strat-
egy for prevention and also controlling the chronic chlamydial infection.
Like in many other human pathogens such as Yersinia, Salmonella,
Shigella, Pseudomonas aeruginosa and pathogenic E. coli, C. pneumoniae pos-
sesses a TTSS, enabling the bacteria to secrete effector proteins into the cytosol of
the infected cell [15, 16]. This system is active during the intracellular phase of the
chlamydial replicative cycle and is responsible for both the insertion of
chlamydial proteins into the inclusion membrane that separates the growing
chlamydial microcolony from the host cell cytoplasm, and also for secretion of
proteins into the host cell cytoplasm which modulates the cell response to ongoing
chlamydial replication. The protein encoded by lcrE is homologous to Yersinia
YopN, a surface protein [17] thought to be a TTSS response regulator, which
senses either a host cell contact in vivo or Ca2+ concentration in vitro. It is located
at the outermost position in the TTSS structure [18]. The fact that LcrE protein ex-
posed in the EB suggests that the TTSS apparatus may also be fully assembled in
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extracellular chlamydiae, possibly to be used in early events of cell infection, e.g.
in order to assist the entry of chlamydiae into the host cell and the successful estab-
lishment of the early chlamydial inclusion vacuole [19].
Herrmann et al. [20] detected increasing expression of LcrE towards the
end of the C. pneumoniae infection cycle. The fact that LcrE appears to be pre-
sented to antibodies on the surface of EB makes this protein a possible vaccine
candidate.
Sambri et al. [21] described a protective effect of recombinant LcrE protein
mixed with Freund’s adjuvant given subcutaneously against C. pneumoniae chal-
lenge in a hamster model. The protective effect of immunization with LcrE protein
mixed with Freund’s or Alum adjuvant against experimental C. pneumoniae in-
fection in mice was earlier described by our group [22]. Studies have shown that
cell-mediated immunity is necessary for protection against C. pneumoniae in
mice. In immunization models DNA has been used to induce Th1 type immunity
against C. pneumoniae. In several studies, a partial protection against the infection
has been observed in mice vaccinated with naked DNA carrying genes for major
outer membrane protein, 60 kDa heat shock protein or ADP/ATP translocase
[23–25].
The purpose of this study was to test the immunogenicity and the protective
ability of intramuscular lcrE-DNA immunization and lcrE-DNA priming/recom-
binant LcrE protein booster immunization regime against C. pneumoniae infec-
tion in mice.
Materials and Methods
Bacterial strains and growth conditions
E. coli DH5a, E. coli HB101 and C. pneumoniae CWL029 (ATCC) strains
were used. E. coli strains were routinely grown in LB (Luria–Bertani) medium
supplemented with the appropriate antibiotic(s) if they carry plasmids.
Plasmid constructions
A 1200 bp fragment containing the lcrE (GeneID: 895078; Locus tag:
CPn0324) gene was amplified by PCR, using the following primers: E1 5’-GGA
GGC ATA TGG CAG CAT CA-3’ and E2 5’-CAC AGG ATC CGT ATT GGT
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TTT GCA TGG C-3’ for ligation to prokaryotic expression vector (as we de-
scribed previously), and the resulting plasmid was pLCRE [22]); and: E3 5’- GCT
AAG CTT ATG GCA GCA TCA GGA G -3’ and E4 5’- TTA GGG CCC GTA
TTG GTT TTG CAT GGC -3’ for ligation to eukaryotic expression vector, C.
pneumoniae CWL029 DNA was used as template.
PCR was performed in a GeneAmp II thermocycler (Applied Biosystems,
Foster City, CA, USA) with Advantage GC cDNA polymerase (Clontech, Moun-
tain View, CA, USA) and the amplification conditions were set as recommended
by the manufacturer. The amplified DNA for eukaryotic expression vector
(pRC) [27] was digested with HindIII and ApaI and inserted into the pRC by
digesting it with the same enzymes. The resulting plasmid was pRCLcrE. For
DNA immunization we purified recombinant pRCLcrE and pRC plasmid in a
large scale by GenElute™ HP Endotoxin – Free Plasmid Megaprep Kit from
Sigma.
Expression and purification of LcrE
For over-expression, E. coli HB101(pGP1-4) cells carrying pLCRE
plasmid were grown and treated according to the method of Tabor and Richardson
[28] as it was described previously [22].
For the protein purification cell lysates from E. coli were prepared by sus-
pending the frozen cells in CelLytic B-II (Sigma) with protease inhibitors. Recom-
binant protein was purified by using TALON CellThru Resin (Clontech) accord-
ing to the manufacturer’s instructions.
Immunization method
Specific-pathogen-free 13-week-old, female BALB/c mice were obtained
from Charles River Laboratories UK (Kent, England). Mice were maintained un-
der standard husbandry conditions at the animal facility of the Department of
Medical Microbiology and Immunobiology, University of Szeged and were given
food and water ad libitum. The mice in groups of 10 were immunized: (Group 1)
with 50 µg pRC plasmid intramuscularly once and 4 weeks later with the puri-
fied LcrE protein diluted in PBS at a dose of 20 µg mixed with 25 µl Alum (Alumi-
num hydroxide Gel, Sigma) in 150 µl subcutaneously into the tail base; or (Group
2) with 50 µg pRCLcrE plasmid intramuscularly two times with 4-week interval,
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or (Group 3) with 50 µg pRCLcrE plasmid intramuscularly once and 4 weeks
later with 20 µg LcrE protein combined with Alum adjuvant. As control we used
Group 4; mice were immunized with 50 µg pRC plasmid intramuscularly two
times with 4-week interval. Two weeks after the last immunization blood was col-
lected in heparinized capillaries from the retro-orbital plexus.
Challenging the immunized mice
Two weeks after the last immunization mice were challenged with 4 × 105
inclusion forming units (IFU) of C. pneumoniae (CWL029) in 25 µl PBS
intranasally under pentobarbital sodium anaesthesia. Seven days after infection
the mice were sacrificed. By heart puncture blood was collected in heparin. The
lungs were removed and homogenized mechanically in 2 ml of sucrose-phos-
phate-glutamic acid buffer (SPG) for cultivation of bacteria.
All animal experiments complied with the University of Szeged Guidelines
for the Use of Laboratory Animals.
Western blot
Purified LcrE protein was heated to 95°C for 5 min in sample buffer, and
the protein was separated by 10% SDS-PAGE. The separated protein was blotted
onto a polyvinylidene difluoride membrane (SERVA Heidelberg, Germany). The
membranes were blocked overnight at 4°C with PBS containing 5% skim milk and
0.05% Tween 20. Membranes were probed with immunized mouse sera (1:50 di-
lution in PBS containing 5% skim milk and 0.05% Tween 20). After washings, the
filter was incubated with HRP-conjugated anti-mouse IgG, and the colour was de-
veloped using diaminobenzidine tetrahydrochloride (DAB, Sigma–Aldrich
Chemie GmbH, Steinheim, Germany) with hydrogen peroxide in 10 mM Tris
pH 7.5.
Inoculum preparation and culturing of C. pneumoniae from the lungs
C. pneumoniae was propagated in HEp-2 cells (ATCC) as described earlier
[29]. The partially purified and concentrated EBs were aliquoted and stored at
–80°C until use. The titre of the infectious EBs was determined by inoculation of
Acta Microbiologica et Immunologica Hungarica 58, 2011
DNA IMMUNIZATION AGAINST CHLAMYDOPHILA PNEUMONIAE 127
serial dilutions of the EB preparation onto HEp-2 monolayers, and after 48 h cul-
ture cells were fixed with acetone and stained with MOMP (major outer mem-
brane protein of C. pneumoniae)-specific monoclonal antibody and FITC-labelled
anti-mouse IgG (Sigma). The number of C. pneumoniae inclusions was counted
under a UV microscope, and the titre was expressed as IFU/ml. Lung homo-
genates from individual mice were centrifuged (10 min, 400 g), serial dilutions of
the supernatants were inoculated onto HEp-2 cell monolayers and the titre
(IFU/ml) of C. pneumoniae was determined as described for the titration of the
C. pneumoniae inoculum.
ELISA tests
LcrE-specific antibodies were detected by ELISA, using plates coated with
recombinant LcrE protein (100 ng/well), and horseradish-peroxidase (HRP)-con-
jugated secondary antibodies (-mouse IgG-HRP, Sigma, -mouse IgG1 and
IgG2a-HRP, Biosource) was used for detection.
Statistical analysis
Statistical analysis of the data was carried out by GraphPad Prism 5 soft-
ware using Wilcoxon-Mann-Whitney two-sample test. Differences were consid-
ered significant at P < 0.05.
Results
Level of LcrE specific IgG in the sera in the immunized mice
All of the mice immunized with LcrE protein mixed with Alum adjuvant,
and most of the (7/10) mice immunized with pRCLcrE responded with LcrE spe-
cific antibody production. LcrE-specific IgG was detected by ELISA. There was a
tendency for higher LcrE-specific IgG level (p = 0.0625) in pRCLcrE-primed
and LcrE protein boosted (Group 3) mice compared to non-primed mice (Group 1)
(Figure 1).
Significant LcrE-specific IgG1 production was detected in the sera of LcrE
protein immunized mice, however, the IgG2a level was low in mice without
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pRCLcrE priming (Figure 2). Mice immunized with pRCLcrE plasmid only
produced relatively higher level of LcrE-specific IgG2a antibody. Boosting the
immune response in pRCLcrE-primed mice with LcrE protein raised not only
the IgG1 but also the IgG2a level. The higher relative IgG2a level indicates a
Th1-biased response in the case of DNA immunized mice irrespective of the na-
ture of the booster inoculation.
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Figure 1. Two weeks after the last immunization sera were tested by LcrE-specific ELISA at dilution of
1:100. LcrE-specific IgG was detected in pRC+LcrE protein immunized, in 2 × pRCLcrE-immunized
and in pRCLcrE-primed and LcrE protein boosted mice in contrast to the 2 × pRC-immunized mice
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Figure 2. LcrE-specific IgG1 and IgG2a levels in the sera of immunized and C. pneumoniae challenged
mice. Isotype of LcrE-specific IgG in the sera of immunized mice was measured by ELISA. Symbols rep-
resent OD values measured with sera of individual mice. Sera were tested at a dilution of 1:800 for IgG1,
and 1:100 for IgG2a
pRC+LcrE prot. 2×pRCLcrE pRCLcrE+LcrE prot. 2×pRC
Western blot analysis of pRCLcrE-induced antibodies
The immunogenicity of the eukaryotic expression vector (pRCLcrE) in
mice and the LcrE-specificity of the produced antibodies were confirmed by
Western blot (Figure 3) using PAGE-separated purified LcrE protein as antigen.
Identity of purified LcrE protein was confirmed by MALDI-TOF mass spectrome-
try previously [30]. Sera of mice from Group 3 (immunized 2 × pRCLcrE) re-
acted with the band at the position corresponding to the molecular weight of LcrE
protein similarly to the sera of LcrE protein immunized-mice of the earlier pub-
lished experiment [22].
Protection against C. pneumoniae infection as measured by culturing
of C. pneumoniae from the lungs
To find out whether lcrE applied in DNA vaccine can induce protective im-
mune response against C. pneumoniae infection, C. pneumoniae titres in the lungs
of immunized and control mice were compared. The reduction in C. pneumoniae
burden in the lungs was 37% in mice immunized with LcrE protein mixed with
Alum adjuvant (Group 1); 55% in pRCLcrE-immunized mice (Group 2) and
nearly 72% in pRCLcrE-primed and LcrE protein boosted mice (Group 3) when
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Figure 3. Sera from immunized mice were tested in Western blot assay. Purified LcrE protein was probed
with sera of 2 × pRCLcrE-immunized mice (lane 1), 2 × pRC-immunized mice (lane 2) and
3 × LcrE protein+Alum immunized mice (lane 3) [22]
compared to pRC-immunized controls (Group 4) (Figure 4). This latter compari-
son showed significant difference with a P value of 0.01.
Discussion
C. pneumoniae has generated huge attention during the last decade, not
only as a respiratory pathogen but because of its association with a number of
acute and chronic diseases, including atherosclerosis, Alzheimer’s disease and
multiple sclerosis [29–32]. The true linkage and causality of C. pneumoniae infec-
tion in the development of chronic manifestations is poorly understood. Since an-
tibiotics cannot fully inhibit chlamydial growth and because of the incomplete
protection induced by natural infection, the development of an effective vaccine
would be desirable to control the infections caused by this highly prevalent patho-
gen. With recent advances in chlamydial genomics and proteomics, a preference
has developed for subunit vaccines. The multi-subunit approach to chlamydia
vaccine will likely induce an effective long-lasting immunity. Structural proteins
of type III secretion system are expected to be surface exposed and required for in-
fection of host cells, thus, these are attractive vaccine candidates to investigate
[16, 33–36].
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Figure 4. C. pneumoniae titres in the lungs of LcrE-immunized mice after C. pneumoniae challenge.
Lung homogenates were inoculated onto HEp-2 cell monolayers and chlamydial inclusions were detected
by indirect immunofluorescence, using MOMP-specific monoclonal and FITC-labelled secondary anti-
bodies. The titre of C. pneumoniae in the lungs of pRCLcrE+LcrE protein immunized mice was signifi-
cantly (* P = 0.01) lower than in lungs of control (2 × pRC-immunized) mice
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Protective effect of LcrE-specific immunity against C. pneumoniae infec-
tion in animal models has been studied. The results of our published experiments
[22] are in agreement with previous reports [21, 26] that LcrE protein is an antigen
with considerable potential as a vaccine subunit and in this study we confirmed
that this antigen has protective effect formulated as a DNA vaccine, too.
In our present study we show that we cloned lcrE gene into a eukaryotic ex-
pression vector, and lcrE-DNA immunization induced protective response against
C. pneumoniae infection similar to that evoked by a single LcrE protein immuni-
zation. Moreover, in a prime-boost regime, i.e. lcrE-DNA/LcrE protein vaccina-
tion, the protective effect reached 72% in respect of lung bacterial burden. This
level of protection is significant and comparable to that achieved by multiple sub-
cutaneous injection of LcrE protein mixed with Alum adjuvant as published ear-
lier [22]. Our findings are that pRCLcrE immunization induces an immune re-
sponse shifted towards Th1 type pathway characterized by increased IgG2a pro-
duction, and immunization with LcrE protein which generates an IgG1-dominated
Th2 type response did not alter the DNA priming-polarized Th1 type response in
DNA-primed and protein-boosted mice. Further experiments with improved im-
munization regimens or modified plasmid vectors are planned for inducing an in-
creased level of antibody and/or cellular response potentially leading to better pro-
tection.
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Mycobacterium smegmatis is a species of rapidly growing saprophytes with a
number of properties that make it an effective vaccine vector. Recombinant M.
smegmatis expressing protective antigens of different pathogens and molecules modu-
lating the immune responses offers some potential for reduction of the burden of tuber-
culosis, HIV and hepatitis B infections. This paper discusses the molecular methods
used to generate recombinant M. smegmatis and the results obtained with some of
these recombinants.
Keywords: Mycobacterium smegmatis, vaccination, recombinant technology
Introduction
The genus Mycobacterium comprises approximately 140 well-character-
ized species [1–4]. Throughout the centuries, two well-known species, Mycobac-
terium tuberculosis and M. leprae, have been frequent causes of immense human
suffering. In 2009, 1.3–1.4 million patients of the HIV-negative and an additional
0.4 million of the HIV-positive people died from tuberculosis (TB). Furthermore
9.4 million new TB cases were recorded (including 3.3 million women) [5, 6].
Leprosy afflicts more than 10 million people, primarily in developing countries.
M. tuberculosis and mycobacteria of the M. avium-intracellulare-scrofulaceum
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group are pathogens of patients with acquired immune deficiency syndrome.
However, the majority of mycobacteria are present in the environment as
saprophytes.
M. smegmatis, first identified in 1884, is a rapidly growing saprophyte, it
can propagate one generation every 1–3 h. It is non-pathogenic and commensal in
humans [7, 8], and it acts as a powerful cell immunity adjuvant. Unlike other
mycobacterial species, such as M. tuberculosis, that survive in host cells by inhib-
iting phagosome maturation, M. smegmatis is rapidly destroyed by pha-
golysosomal proteases in the phagosomes of infected cells [9, 10]. M. smegmatis
has a number of properties that can make it an effective vaccine vector. This
fast-growing Mycobacterium is unable to arrest phagolysosome maturation and
cannot evade intracellular killing [11–14]. Moreover, its rapid clearance by the
host differs from that of the M. tuberculosis or even the vaccine strain M. bovis ba-
cillus Calmette-Guérin [10]. Furthermore, M. smegmatis has been used as a vac-
cine vector because it activates dendritic cells and induces CD8-mediated immune
responses [15–18]. Finally, killed M. smegmatis has been shown to provide the
same adjuvant activity as M. tuberculosis during the induction of experimental au-
toimmune encephalomyelitis [19].
The role of M. smegmatis in immunotherapy
Structural components of mycobacteria have been studied for immune-po-
tentiating effects since the 1970s. Ribi et al. [20] proved the antitumour activity of
the cell walls of M. tuberculosis, M. bovis, M. phlei and M. smegmatis. Schwartz et
al. [21] demonstrated inhibition of the growth of sarcoma cells in guinea pigs after
infection with different species of mycobacteria. The effect was most pronounced
at the time of the maximum biological activity of the applied mycobacterium. As a
curiosity, mention should be made of the study of the synthesis of vitamin B12 by
several mycobacterial strains, among them M. smegmatis [22].
Recombinant technology applied in M. smegmatis
Molecular mycobacteriology emerged in the 1980s. In 1985, different re-
search groups demonstrated that genes from M. tuberculosis, M. leprae and M.
bovis BCG could be cloned and expressed in Escherichia coli [23–26]. The basic
tools for the mycobacterial genetic system were developed by Jacobs et al. in 1987
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[27]. They devised the methodology for efficient gene transfer in mycobacteria by
generating recombinant shuttle plasmids which are chimaeras containing
mycobacteriophage DNA and an E. coli cosmid. These can replicate in E. coli as
plasmids and in mycobacteria as phages and transfer DNA between both genera.
These shuttle vectors for the first time permit the introduction of foreign DNA by
electroporation into M. smegmatis and BCG. Through the expression of genes of
protective antigens from a variety of pathogens, it became feasible to convert cul-
tivable mycobacteria into useful multivaccine vehicles. The efficient plasmid
transformation of M. smegmatis was elaborated. The identified high-efficiency
(more than 105 transformants per microgram of plasmid DNA) transformable mu-
tant strain of M. smegmatis (mc2155) proved to be an extremely useful model sys-
tem for the study of various aspects of mycobacterial physiology [28]. A method
which allowed the stable integration of DNA fragments at a single site in the chro-
mosome of M. smegmatis was developed by Martín et al. [29], who devised a vec-
tor containing an E. coli replicon, the kanamycin resistance gene for selection in
mycobacteria and a fragment from Streptomyces plasmid pSAM2. However, the
most used integrative plasmids are derived from L5 mycobacteriophage by Lee et
al. [30]. The site-specific integration vectors transform mycobacteria with high ef-
ficiency to produce stable recombinants that contain a well-defined single-copy
insert of the plasmid, these vectors can be used to efficiently insert large segments
of DNA into mycobacteria.
The development of vectors and methodologies to introduce foreign DNA
into members of the genus Mycobacterium has led to new approaches for the in-
vestigation of these important bacteria.
Recombinant M. smegmatis vectors in the defence
against infectious diseases
IL-12/GLS (granulysin), Antigen 85B and ESAT6-CFP10 fusion protein
A recombinant M. smegmatis was constructed as a potential therapeutic
vaccine against tuberculosis by Yi et al. [31]. Viable non-pathogenic M.
smegmatis (ATCC607) carrying the pZM03 plasmid [a co-expression plasmid en-
coding human granulysin (GLS) and murine interleukin 12 (IL-12)] was used as a
therapeutic vaccine to induce strong specific immunity against M. tuberculosis in
vivo. Mice vaccinated with the therapeutic recombinant M. smegmatis (clone
pZ607) displayed an enhanced immune response to M. tuberculosis-specific anti-
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gen. This enhancement proved to be not less than (as assessed by the detection of
IL-12 and IFN-gamma in the serum, the anti-purified protein derivative [PPD]
sIgA in the broncho-alveolar lavage fluid, and the proliferation and IFN-gamma
secretion by the splenocytes in response to PPD) or even higher than (as assessed
via anti-PPD IgG2a in the serum) that in mice immunized with BCG. Since this
therapeutic vaccine can induce strong specific Th1 responses against M. tubercu-
losis in BALB/c mice and causes no obvious harm to the host, the recombinant
vaccine might be a candidate therapeutic vaccine against tuberculosis. Yang et al.
[32] later reported that a recombinant M. smegmatis carrying pZM03 exerted com-
bined anti-tuberculosis activity, i.e. immunotherapeutic effects with stimulation
of the Th1 response, and the antibacterial activity of GLS.
Mycobacterial antigen 85B-induced immunogenicity is a strong correlate
of vaccine-induced immunity against M. tuberculosis in mice. Wild-type M.
smegmatis contains genes that encode the proteins of antigen 85B, but perhaps be-
cause of the secretion of these proteins is minimal, wild-type M. smegmatis is un-
able to induce protection against challenge with tuberculosis in mice. Lindsey et
al. [33] over-expressed the immunodominant antigen 85B in M. smegmatis. Im-
munization with this recombinant mycobacteria induced protection against tuber-
culosis by enhanced T cell response in lungs.
Zhang et al. [34] evaluated a recombinant vaccine prepared from M. smeg-
matis that expresses a fusion of early secreted antigenic target 6-kDa antigen
(ESAT6) and culture filtrate protein 10 (CFP10). These authors immunized mice
with the recombinant M. smegmatis expressing the ESAT6-CFP10 fusion protein
(rM.S-e6c10) or with BCG. The mice in the recombinant M. smegmatis group had
a significantly higher titre of anti-ESAT6-CFP10 antibodies than did animals in
control groups. Mice immunized with recombinant M. smegmatis produced sig-
nificantly higher levels of IFN- and IL-2 than mice in the BCG-immunized
group. Finally, immunization with recombinant M. smegmatis dramatically re-
duced the number of M. tuberculosis colony-forming units in the lungs of M. tu-
berculosis challenged mice, indicating its potential in clinical application.
Cowpox virus B5 (CPXV-B5)
Barefoot et al. [35] compared different vaccine vectors expressing a 35kDa
secreted form of the Cowpox virus B5 antigen, which is known to be a strong in-
ducer of the humoral immune response. B5 is conserved among poxviruses and
has homologues among many mammalian orthopoxviruses, including variola and
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vaccinia. The B5-specific immune response is of relevance as concerns the
biodefence. The B5 protein was produced by E. coli carrying a plasmid and was
used as a purified recombinant protein, or was expressed by different vectors such
as a non-replicating recombinant adenovirus, a highly attenuated replication com-
petent vesicular stomatitis virus, Venezuelan encephalitis virus replicon particles,
or recombinant M. smegmatis. M. smegmatis expressed very low levels of the B5
protein which could not be readily detected by Western blotting. All other vectors
expressed robust levels of the B5 protein. While the expression of B5 by M.
smegmatis was barely detectable by Western blotting, the presence of the gene
was confirmed by sequencing. All vectors induced detectable serum antibody
titres except M. smegmatis.
Human immunodeficiency virus proteins
M. smegmatis was engineered by Cayabyab et al. [16] as a vector express-
ing full-length HIV type 1 (HIV-1) HXBc2 envelope protein (gp120). Mice were
inoculated twice with recombinant M. smegmatis expressing gp120, at an interval
of 10 weeks. However, the peak responses after the two inoculations were not
greater than those seen following a single inoculation. The responses in the
boosted mice declined thereafter, but remained detectable even 1 year following
the initial immunization. Hovav et al. [18] showed that a recombinant
mycobacterial vector induced a cellular immune response that is biased toward
memory cells and that can expand dramatically on re-exposure to an HIV-1 enve-
lope antigen. Their observation that a small number of M. smegmatis-elicited
p18-specific CD8+ T-cells can expand into large populations of functionally com-
petent cytotoxic-T-lymphocytes following heterologous boosting with recombi-
nant gp140-expressing adenovirus vector suggests that recombinant M. smeg-
matis may be useful as a priming vector in prime/boost vaccine regimens.
Yu et al. [36] described recombinant M. smegmatis vectors constructed to
express the HIV-1 group M consensus env gene CON6 as either a surface, or an
intracellular, or a secreted protein and determined the expression of the insert and
the immunogenicity of these constructs. They demonstrated the ability of HIV-1
Env protein expressed by the recombinant M. smegmatis to induce mucosal T-cell
immune responses after immunization. Recombinant M. smegmatis induced lower
anti-HIV-1 T-cell responses than did a recombinant adenovirus (rAd)-recombi-
nant vaccinia virus (rVV) prime/boost regimen in the spleen, but it induced
IFN-gamma responses similar to those induced by rAd-rVV in the reproductive
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tract and lungs of female mice, as detected by an enzyme-linked immunospot as-
say. These data demonstrate that recombinant M. smegmatis is immunogenic for
the induction of HIV-1 T-cell responses at mucosal surfaces. The authors found
that neither a prime nor a boost with recombinant M. smegmatis alone could in-
duce any detectable anti-HIV-1 Env antibody. However, a single boost of the re-
combinant M. smegmatis-immunized mice with recombinant CON6 gp140CF
protein induced higher anti-Env antibody titres than those observed in mice immu-
nized with CON6 gp140CF protein alone or with empty recombinant M. smeg-
matis plus Env protein.
Mycobacteria are also regarded as promising vectors for DNA vaccine de-
livery. Mo et al. [37] characterized the ability of mycobacteria harbouring a
plasmid encoding the fluorescence reporter gene under the control of a eukaryotic
promoter to transfer the gene into mammalian cells, and the effects of various bac-
terial chromosomal mutations on the efficiency of transfer in vivo and in vitro.
They observed that M. smegmatis strains (referred to as RepHigh M. smegmatis)
that overexpressed replication proteins (Reps) responsible for initiation of the rep-
lication and copy number of mycobacterial plasmids increased the plasmid copy
number up to 10-fold and transferred genes to the infected HeLa (human cervical
adenocarcinoma) or J774 (murine macrophage) cells upon infection up to 3.5-fold
more frequently than did a control M. smegmatis strain (RepWt M. smegmatis).
Vaccination with RepHigh M. smegmatis strains harbouring a plasmid encoding
HIV type 1 gp120 under the control of a eukaryotic promoter generated
gp120-specific CD8 T-cell responses among peripheral blood mononuclear cells
in mice at an up to 3-fold higher frequency than that following vaccination with
RepWt M. smegmatis strains harbouring the same plasmid. The frequencies of
gp120-specific CD8+ T-cell responses observed after immunization with the re-
combinant M. smegmatis were lower than those observed after intramuscular
DNA immunization with a eukaryotic expression vector (pgp120h
E), however, the
immunization with the M. smegmatis recombinant generated more durable mem-
ory T-cells as compared to intramuscular DNA vaccination. These observations
encourage the further development of mycobacteria as efficient DNA vaccine de-
livery vectors.
Hepatitis B virus proteins
Yue et al. [38] constructed eukaryotic and prokaryotic expression vectors
and recombinant M. smegmatis which carried the fused genes of the CS1 antigen,
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a fusion protein that comprises a truncated core protein (amino acids 1–155) and
the preS1 peptide (amino acids 1–55) of the protein responsible for the attachment
of the hepatitis B virus (HBV).
The antigen-specific cellular and humoral immune responses were charac-
terized after inoculation with the recombinant M. smegmatis or a recombinant
DNA based vaccine, which expressed the fused proteins in vitro. CS1-specific
DNA immunization induced only a minor humoral response and low levels of T
cell immunity. Vaccination with live recombinant M. smegmatis induced a stron-
ger cellular immune response and a longer period of humoral immune response,
which are crucial for virus-specific vaccines. Thus, this recombinant M.
smegmatis has a potential for the prevention of HBV infection.
Outer membrane protein 26 kDa antigen (Omp26) of Helicobacter pylori
H. pylori induces chronic inflammation of the stomach mucosa, causing
chronic gastritis and peptic ulcer. The bacteria infect approximately 50% of the
world’s population. Studies in mice have shown that prophylactic or therapeutic
oral immunization with H. pylori lysate results in significant, but rarely sterilizing,
immunity against H. pylori. Lü et al. [39] developed a recombinant M. smegmatis
expressing the Omp26 antigen, then evaluated the capacity of the recombinant to
reduce H. pylori colonization in the stomach and induce immune responses after
therapeutic immunization in mice. The oral therapeutic immunization with recom-
binant M. smegmatis induced a significant reduction in the number of H. pylori
bacteria in the stomachs, compared to the control infected mice. The serum anti-H.
pylori specific antibody level was increased with a Th1 and Th2 profiles and also a
local overproduction of cytokines in the stomach and spleen was observed. These
results suggested that Omp26 is a promising vaccine candidate antigen for use in a
therapeutic vaccine against H. pylori, and M. smegmatis provide new tools to ana-
lyse the immune mechanisms mediating protection and the identification of pro-
teins which are important in protection.
Conclusion
Several recombinant M. smegmatis have been produced and evaluated in
animal models as new vaccine candidates. It is hoped that the utilization of one or
more of these new vaccines, combined with the development of modern produc-
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tion technologies, will contribute substantially to the control of these important in-
fectious diseases.
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